{"title":"EPO Protein: Target Overview, Research Applications, and Selection Guide","description":"","products":[{"product_id":"recombinant-human-epor-protein-his-tag-bl-2273np","title":"Recombinant Human EPO-R Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin Receptor is produced by our Mammalian expression system and the target gene encoding Ala25-Pro250 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP19235\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpoR; EPO-R; Erythropoietin R; erythropoietin receptor; MGC138358\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin (Epo), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The biological effects of Epo are mediated by the erythropoietin receptor (Epo R). The presence of a soluble form of the Epo R has also been detected on human sera. Recombinant soluble Epo R binds Epo with high affinity and is a potent Epo antagonist.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25.9 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-38 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 8% Trehalose, 3% Glycine, 0.05% Tween 80, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.; Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein.; [Isoform EPOR-S]: Secreted. Note=Secreted and located to the cell surface.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3416           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133100           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2057           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000222139           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30044226            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            EpoR role in the proliferation and survival of non-small cell lung cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29345289            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results highlight the high intrinsic specificity of transmembrane domain interactions, demonstrate that a single methyl group can dictate specificity, and define the minimal chemical difference that can modulate the specificity of transmembrane domain interactions and the activity of transmembrane proteins.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28869036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study reports for the first evidence that EPOR modulates breast cancer cell morphology changes upon tamoxifen treatment, which result in increased formation of cell protrusions and subsequent cell death and, proposes sustained AKT phosphorylation in EPOR-overexpressing cells as a mechanism that can lead to EPOR-induced tamoxifen resistance.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28714517            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Authors retrospectively investigated whether TFR2 isoforms and EPOR are differentially expressed in MDS patients and whether the expression is associated with patients' clinical outcomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26914246            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPOR expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO-mediated EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro            \u003ca rel=\"nofollow\"\u003e             PMID:                        27581518            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO could directly promote tumor progression via EPO receptor-expressing macrophages            \u003ca rel=\"nofollow\"\u003e             PMID:                        27262376            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA. CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27640183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPOR is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HIF-1alpha and EPO-R may be an indicator of the aggressiveness of invasive breast cancers            \u003ca rel=\"nofollow\"\u003e             PMID:                        27629849            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results identify EPOR as the secondbona fidehydroxylation-dependent substrate of VHL that potentially influences oxygen homeostasis and contributes to the complex genotype-phenotype correlation in VHL disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26846855            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We report for a first time that functional EpoR is expressed in human rhabdomyosarcoma cell lines as well as by primary tumors from RMS patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            erythrocyte lineage enforces exclusivity through upregulation of EKLF and its lineage-specific cytokine receptor (EpoR) while inhibiting both FLI-1 and the receptor TpoR (also known as MPL) for the opposing megakaryocyte lineage            \u003ca rel=\"nofollow\"\u003e             PMID:                        26159733            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A new point mutation in EPOR induces a short deletion in congenital erythrocytosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26010769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that erythropoietin receptor antagonist EMP9 suppressed hemoglobin synthesis in xenografts of HeLa cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25874769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that erythropoietin receptor (EPOR) could be a target to overcome therapeutic resistance toward ionizing radiation or temozolomide.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25544764            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles            \u003ca rel=\"nofollow\"\u003e             PMID:                        25418301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            while EPO can stimulate NO production, NO in turn can regulate EPOR expression in endothelial cells during hypoxia            \u003ca rel=\"nofollow\"\u003e             PMID:                        24518819            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In HBV-related HCC, the levels of EpoR mRNA and protein in non-tumour cirrhotic livers were positively correlated with tumour cell differentiation, which is a favourable predictor of disease-specific survival.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23496059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study reveals high EPOR level as a potential novel positive prognostic marker in human lung lung adenocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24155958            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            3 novel EPOR mutations in primary familial and congenital polycythemia--Del1377-1411, a C1370A and G1445--were chimerized with EGFR to study signalling and metabolism of the chimeric receptors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24533580            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that erythropoietin receptor (EPOR) protein is expressed in breast cancer cells, where it appears to promote proliferation by an EPO-independent mechanism in estrogen receptor alpha (ERalpha) expressing breast cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24502950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Epo-R is expressed in bone marrow-derived macrophages from multiple myeloma and monoclonal gammopathy of undetermined significance patients. The Epo\/Epo-R pathway may be involved in the regulation of angiogenic response occurring in MM.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23881169            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that adipose tissue-specific disruption of EPO receptor does not alter adipose tissue expansion, adipocyte morphology, insulin resistance, inflammation, or angiogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23885016            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sp1 may significantly affect the number of EPO-R molecules present on the surface of activated CD4(+) lymphocytes            \u003ca rel=\"nofollow\"\u003e             PMID:                        23577103            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR expression may be involved in tumor progression and proliferation in HER2-positive breast cancer.EPOR contributes to the mechanism of trastuzumab resistance in breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23117856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TAL1 binds to the EPO-R promoter to activate EPO-R expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        22982397            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPOR expression in OSCC is associated with an aggressive tumor behavior and poorer prognosis in the univariate analysis among patients with OSCC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22639817            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is capable of downregulating erythropoietin receptor when it acts early within HepG2 cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22227182            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the biology of the EpoR in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        22552716            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The absence of functional Epo receptor activity in human skeletal muscle indicates that the long-term effects are indirect and probably related to an increased oxidative capacity in this tissue            \u003ca rel=\"nofollow\"\u003e             PMID:                        22384088            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a critical role for membrane raft in recruitment and assembly of Epo-R and signal intermediates into discrete membrane signaling units            \u003ca rel=\"nofollow\"\u003e             PMID:                        22509308            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            New knowledge concerning regulated EPOR expression and trafficking therefore is provided, together with new insight into mechanisms via which mutated EPOR-T polycythemia alleles dysregulate the erythron.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22253704            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data support that EpoR is functional in melanoma and EpoR activation may promote melanoma progression, and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21860424            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of EPOR and TPOR on CD34+ CD59+ bone marrow cells are significantly higher than those on CD34+ CD59- cells of paroxysmal nocturnal hemoglobinuria patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22338178            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            STAT5 phosphorylation levels of EPO and TPO receptors are elevated in bone marrow cells of patients with paroxysmal nocturnal hemoglobinuria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22093990            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ETV6-RUNX1 directly activates ectopic expression of a functional EPOR and provides cell survival signals that may contribute critically to persistence of covert premalignant clones in children.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21900195            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR signalling in tumour cells is involved in the control of glioma growth.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21749867            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO-R cytosolic lysine residues enhance receptor function, most probably through ubiquitination and\/or other post-translational modifications.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21291419            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Epo\/EpoR complex plays a critical role in the adhesion and migration of rat fibroblasts, and its functional inactivation is associated with PLC-gammal-dependent reduction of cell-matrix adhesion and this also affects cell migration.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21360263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Detected is a novel heterozygous frameshift mutation in exon 8 of the EPOR resulting in primary familial and congenital polycythaemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21437635            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR is expressed in cells of acute leukemia, but the expression level in low. The EPOR expression rate shows no significant difference between AML and ALL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19099624            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EpoR is associated with angiogenesis in glioma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20614229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tumor vessels exhibited EpoR, pJAK-2, and pSTAT-5 immunoreactivity            \u003ca rel=\"nofollow\"\u003e             PMID:                        20336349            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that spermatozoa express EPO receptor on plasma membrane, which might act to protect these cells from damage after ejaculation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20884294            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR signaling is absolutely required for Parvovirus B19 replication in ex vivo-expanded erythroid progenitor cells after initial virus entry and at least partly accounts for the remarkable tropism of B19V infection for human erythroid progenitors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20861249            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a regulatory role of EPO\/EPOR pathway in human circulating endothelial precursors homeostasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        20700488            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that sEpoR is detectable as a 27kDa protein in the serum of dialysis patients, and that higher serum sEpoR levels correlate with increased erythropoietin requirements.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20169072            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR mRNA was detected in essentially all cell types examined, including primary endothelial, renal, cardiac, and neuronal cells but 10- to 100-fold lower than Epo-responsive cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        20124513            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915048878305,"sku":"BL-2273NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLbKAJPOnAADkf5EvBY8125_1d598883-c7ab-4ac9-8c44-5486a22ae3c6.jpg?v=1685851531"},{"product_id":"recombinant-human-epor-protein-fc-tag-bl-2274np","title":"Recombinant Human EPO-R Protein (C-Fc)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin Receptor is produced by our Mammalian expression system and the target gene encoding Ala25-Pro250 is expressed with a human IgG1 Fc tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP19235\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpoR; EPO-R; Erythropoietin R; erythropoietin receptor; MGC138358\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin (Epo), a glycoprotein produced primarily by the kidney, is the principal factor that regulates erythropoiesis by stimulating the proliferation and differentiation of erythroid progenitor cells. The biological effects of Epo are mediated by the erythropoietin receptor (Epo R). The presence of a soluble form of the Epo R has also been detected on human sera. Recombinant soluble Epo R binds Epo with high affinity and is a potent Epo antagonist.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e52 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e55-75 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of 20mM PB, 6% Trehalose, 4% Mannitol, 0.05% Tween 80, pH 7.5.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg\/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. \u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.; Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein.; [Isoform EPOR-S]: Secreted. Note=Secreted and located to the cell surface.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3416           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133100           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2057           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000222139           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        30044226            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            EpoR role in the proliferation and survival of non-small cell lung cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        29345289            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results highlight the high intrinsic specificity of transmembrane domain interactions, demonstrate that a single methyl group can dictate specificity, and define the minimal chemical difference that can modulate the specificity of transmembrane domain interactions and the activity of transmembrane proteins.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28869036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study reports for the first evidence that EPOR modulates breast cancer cell morphology changes upon tamoxifen treatment, which result in increased formation of cell protrusions and subsequent cell death and, proposes sustained AKT phosphorylation in EPOR-overexpressing cells as a mechanism that can lead to EPOR-induced tamoxifen resistance.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28714517            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Authors retrospectively investigated whether TFR2 isoforms and EPOR are differentially expressed in MDS patients and whether the expression is associated with patients' clinical outcomes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26914246            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPOR expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO-mediated EPOR signaling reduced the viability of myeloma cell lines and of malignant primary plasma cells in vitro            \u003ca rel=\"nofollow\"\u003e             PMID:                        27581518            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO could directly promote tumor progression via EPO receptor-expressing macrophages            \u003ca rel=\"nofollow\"\u003e             PMID:                        27262376            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA. CONCLUSION: Thus, in contradiction to animal studies, Epo treatment within a physiological relevant range in humans does not exert direct effects in a subcutaneous WAT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27640183            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPOR is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            HIF-1alpha and EPO-R may be an indicator of the aggressiveness of invasive breast cancers            \u003ca rel=\"nofollow\"\u003e             PMID:                        27629849            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results identify EPOR as the secondbona fidehydroxylation-dependent substrate of VHL that potentially influences oxygen homeostasis and contributes to the complex genotype-phenotype correlation in VHL disease.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26846855            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We report for a first time that functional EpoR is expressed in human rhabdomyosarcoma cell lines as well as by primary tumors from RMS patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            erythrocyte lineage enforces exclusivity through upregulation of EKLF and its lineage-specific cytokine receptor (EpoR) while inhibiting both FLI-1 and the receptor TpoR (also known as MPL) for the opposing megakaryocyte lineage            \u003ca rel=\"nofollow\"\u003e             PMID:                        26159733            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A new point mutation in EPOR induces a short deletion in congenital erythrocytosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26010769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that erythropoietin receptor antagonist EMP9 suppressed hemoglobin synthesis in xenografts of HeLa cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25874769            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that erythropoietin receptor (EPOR) could be a target to overcome therapeutic resistance toward ionizing radiation or temozolomide.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25544764            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles            \u003ca rel=\"nofollow\"\u003e             PMID:                        25418301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            while EPO can stimulate NO production, NO in turn can regulate EPOR expression in endothelial cells during hypoxia            \u003ca rel=\"nofollow\"\u003e             PMID:                        24518819            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In HBV-related HCC, the levels of EpoR mRNA and protein in non-tumour cirrhotic livers were positively correlated with tumour cell differentiation, which is a favourable predictor of disease-specific survival.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23496059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study reveals high EPOR level as a potential novel positive prognostic marker in human lung lung adenocarcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24155958            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            3 novel EPOR mutations in primary familial and congenital polycythemia--Del1377-1411, a C1370A and G1445--were chimerized with EGFR to study signalling and metabolism of the chimeric receptors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24533580            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that erythropoietin receptor (EPOR) protein is expressed in breast cancer cells, where it appears to promote proliferation by an EPO-independent mechanism in estrogen receptor alpha (ERalpha) expressing breast cancer cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24502950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Epo-R is expressed in bone marrow-derived macrophages from multiple myeloma and monoclonal gammopathy of undetermined significance patients. The Epo\/Epo-R pathway may be involved in the regulation of angiogenic response occurring in MM.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23881169            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that adipose tissue-specific disruption of EPO receptor does not alter adipose tissue expansion, adipocyte morphology, insulin resistance, inflammation, or angiogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23885016            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sp1 may significantly affect the number of EPO-R molecules present on the surface of activated CD4(+) lymphocytes            \u003ca rel=\"nofollow\"\u003e             PMID:                        23577103            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR expression may be involved in tumor progression and proliferation in HER2-positive breast cancer.EPOR contributes to the mechanism of trastuzumab resistance in breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23117856            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            TAL1 binds to the EPO-R promoter to activate EPO-R expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        22982397            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPOR expression in OSCC is associated with an aggressive tumor behavior and poorer prognosis in the univariate analysis among patients with OSCC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22639817            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is capable of downregulating erythropoietin receptor when it acts early within HepG2 cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22227182            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the biology of the EpoR in ovarian cancer cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        22552716            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The absence of functional Epo receptor activity in human skeletal muscle indicates that the long-term effects are indirect and probably related to an increased oxidative capacity in this tissue            \u003ca rel=\"nofollow\"\u003e             PMID:                        22384088            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a critical role for membrane raft in recruitment and assembly of Epo-R and signal intermediates into discrete membrane signaling units            \u003ca rel=\"nofollow\"\u003e             PMID:                        22509308            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            New knowledge concerning regulated EPOR expression and trafficking therefore is provided, together with new insight into mechanisms via which mutated EPOR-T polycythemia alleles dysregulate the erythron.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22253704            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data support that EpoR is functional in melanoma and EpoR activation may promote melanoma progression, and suggest that Epo may stimulate angiogenesis and increase survival of melanoma cells under hypoxic condition in vivo.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21860424            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The expression of EPOR and TPOR on CD34+ CD59+ bone marrow cells are significantly higher than those on CD34+ CD59- cells of paroxysmal nocturnal hemoglobinuria patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22338178            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            STAT5 phosphorylation levels of EPO and TPO receptors are elevated in bone marrow cells of patients with paroxysmal nocturnal hemoglobinuria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22093990            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ETV6-RUNX1 directly activates ectopic expression of a functional EPOR and provides cell survival signals that may contribute critically to persistence of covert premalignant clones in children.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21900195            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR signalling in tumour cells is involved in the control of glioma growth.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21749867            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO-R cytosolic lysine residues enhance receptor function, most probably through ubiquitination and\/or other post-translational modifications.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21291419            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Epo\/EpoR complex plays a critical role in the adhesion and migration of rat fibroblasts, and its functional inactivation is associated with PLC-gammal-dependent reduction of cell-matrix adhesion and this also affects cell migration.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21360263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Detected is a novel heterozygous frameshift mutation in exon 8 of the EPOR resulting in primary familial and congenital polycythaemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21437635            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR is expressed in cells of acute leukemia, but the expression level in low. The EPOR expression rate shows no significant difference between AML and ALL.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19099624            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EpoR is associated with angiogenesis in glioma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20614229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Tumor vessels exhibited EpoR, pJAK-2, and pSTAT-5 immunoreactivity            \u003ca rel=\"nofollow\"\u003e             PMID:                        20336349            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results suggest that spermatozoa express EPO receptor on plasma membrane, which might act to protect these cells from damage after ejaculation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20884294            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR signaling is absolutely required for Parvovirus B19 replication in ex vivo-expanded erythroid progenitor cells after initial virus entry and at least partly accounts for the remarkable tropism of B19V infection for human erythroid progenitors.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20861249            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a regulatory role of EPO\/EPOR pathway in human circulating endothelial precursors homeostasis            \u003ca rel=\"nofollow\"\u003e             PMID:                        20700488            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data show that sEpoR is detectable as a 27kDa protein in the serum of dialysis patients, and that higher serum sEpoR levels correlate with increased erythropoietin requirements.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20169072            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR mRNA was detected in essentially all cell types examined, including primary endothelial, renal, cardiac, and neuronal cells but 10- to 100-fold lower than Epo-responsive cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        20124513            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43915072798945,"sku":"BL-2274NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLbKADaVoAAC8lcL2S_Y781_cccefaab-93ae-4a09-ad02-042f9bc8dd27.jpg?v=1685852247"},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p15-partial-blit-0967","title":"Recombinant Treponema pallidum \/ T.pallidum p15 (Partial)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant protein is fused at N-terminus with GST tag and contains the Trp. Pallidum p15 immunodominant regions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;95% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e70mM Tris-HCl pH-8, 84mM NaCl, 14mM Glutathione, 30% Glycerol \u0026amp; 0.2% Sarcosil.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486380769,"sku":"BLIT-0967","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p15-partial-his-blit-0968","title":"Recombinant Treponema pallidum \/ T.pallidum p15 (Partial), His","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant 6xHis tag fusion protein is a multimer having a molecular mass of 48kDa and contains the Trp. Pallidum p15 immunodominant regions and six histidines fused at the C- terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;95% pure as determined by SDS- PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e70mM Tris-HCl pH 8.0, 50mM NaCl, 50% Glycerol, 1.5 M Urea.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486479073,"sku":"BLIT-0968","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p17-blit-0969","title":"Recombinant Treponema pallidum \/ T.pallidum p17","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant protein contains the T. Pallidum p17 immunodominant regions. The protein contains beta- galactosidase (114 kDa) fused at the N- terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein protein is \u0026gt;90% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e8M urea, 20mM Tris-HCl pH-8 and10mM B-ME.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486511841,"sku":"BLIT-0969","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p17-partial-blit-0970","title":"Recombinant Treponema pallidum \/ T.pallidum p17 (Partial)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant protein is fused at N-terminus with 6xHis tag and contains the Trp. Pallidum p17 immunodominant regions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;95% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e70mM Tris-HCl pH8.0, 50mM NaCl, 50% Glycerol, 1.5M Urea.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486544609,"sku":"BLIT-0970","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p41-blit-0971","title":"Recombinant Treponema pallidum \/ T.pallidum p41","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.coli derived recombinant protein contains the outer membrane T.Pallidum p41 immunodominant regions. The protein is fused with a Beta-galactosidase tag.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum protein is \u0026gt;90% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e10mM Tris-HCl pH8.0, 1mM EDTA, 1mMDTT and 8M urea.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486610145,"sku":"BLIT-0971","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p41-mosaic-blit-0972","title":"Recombinant Treponema pallidum \/ T.pallidum p41 Mosaic","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.coli derived recombinant protein contains the outer membrane T.Pallidum p41 immunodominant regions. The protein is fused with a GST tag.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;90% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e25mM Tris-HCl pH-8, 60mM NaCl \u0026amp; 50% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486642913,"sku":"BLIT-0972","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p47-blit-0973","title":"Recombinant Treponema pallidum \/ T.pallidum p47","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum subsp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant protein contains the T.Pallidum p47 immunodominant regions. The protein contains beta-galactosidase (114 kDa) fused at the N- terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;95% pure as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e8M urea, 10mM Tris-HCl pH 8.0, 1mM EDTA and 1mM DTT.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486675681,"sku":"BLIT-0973","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-p47-partial-blit-0974","title":"Recombinant Treponema pallidum \/ T.pallidum p47 (Partial)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum subsp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant protein is fused at the C- terminus with a 6xHis Tag and contains the T.Pallidum p47 immunodominant regions.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;95% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e70mM Tris-HCl pH8.0, 50mM NaCl, 50% Glycerol and 1.5M urea.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486905057,"sku":"BLIT-0974","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-tmpa-blit-0975","title":"Recombinant Treponema pallidum \/ T.pallidum TmpA","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived recombinant protein contains the T.Pallidum TmpA immunodominant regions. The protein contains beta- galactosidase (114 kDa) fused at the N- terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema Pallidum protein is \u0026gt;90% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e8M urea, 20mM Tris-HCl pH-8 \u0026amp; 10mM B-ME.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878486970593,"sku":"BLIT-0975","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-treponema-pallidum-t-pallidum-tmpa-partial-blit-0976","title":"Recombinant Treponema pallidum \/ T.pallidum TmpA partial","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eT.pallidum\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eTreponema pallidum is a gram-negative spirochaete bacterium and is considered to be metabolically crippled. There are at least four known subspecies: T. pallidum pallidum, T. pallidum pertenue, T. pallidum carateum and T. pallidum endemicum. The helical structure of T. pallidum pallidum allows it to move in a corkscrew motion through viscous mediums such as mucus. Treponema pallidum sub sp. pallidum has one of the smallest bacterial genomes at 1.14 million base pairs (Mb) and has limited metabolic capabilities, reflecting its adaptation through genome reduction to the rich environment of mammalian tissue.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe E.Coli derived 68kDa recombinant protein contains the Trp. Pallidum TmpA immunodominant regions, 23-41 amino acids and 288-325 amino acids.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eProtein is \u0026gt;95% pure as determined by 10% PAGE (coomassie staining).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e10mM Tris-HCl pH8.0, 20mM DDT, 1mM EDTA and 8M urea.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eApplications\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eAntibody ELISA;  immunogen; WB,  etc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":42878487003361,"sku":"BLIT-0976","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-epo-protein-bl-1638sg","title":"Recombinant Human EPO Protein","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 data-mce-fragment=\"1\" class=\"font_9\"\u003e\n\u003cmeta charset=\"utf-8\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eHost Species\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eP01588\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eErythropoietinRecombinant Human Erythropoietin-Alpha (EPO)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eEPO is predominantly synthesized and secreted by tubular and juxtatubular capillary, endothelial, and interstitial cells of the kidney. Approximately 10-15% of the total amount of EPO comes from extrarenal sources and is predominantly produced by hepatocytes and Kupffer cells of the liver. Approximately 40% of the molecular mass of EPO is due to its glycosylation. Glycosylation is an important factor determining the pharmacokinetic behaviour of EPO in vivo. Non-glycosylated Epo has an extremely short biological half life. Recombinant Human EPO is a glycosylated protein that runs at approximately 35 kDa owing to its glycosylation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human EPO was produced in E. coli. This protein is purified with our unique purification methods.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eSource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e20.0 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor specific purity information on a given lot, see related COA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003e\u0026lt; 1.0 EU per μg of the protein as determined by the LAL method\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant protein is supplied in 50mM Tris-HCl, pH 7.5, 50mM NaCl, 10mM Glutathione, 0.25mM DTT, 0.1mM EDTA, 0.1mM PMSF and 25% glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eThe recombinant protein is stable for up to 12 months at -70°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\" data-mce-style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\" data-mce-style=\"width: 70%;\"\u003eRecombinant Human EPO Protein should be stored should be stored at \u0026lt; -70°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3415           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133170           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2056           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000252723           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29395333            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the implication of alpha-7-nAChR-JAK-2\/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS            \u003ca rel=\"nofollow\"\u003e             PMID:                        29220591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28983059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27853265            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28603097            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28173069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29514032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28553927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27282568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26822707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            age 3 plasma levels of EPO were found related to childhood asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        27434124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28247960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28038963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO dependent regulation pathway of FGF23 gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        29073196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27161360            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        27266727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27981303            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27441662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27190272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +\/- 13.28 h) in comparison to epoetin alpha (8.5 +\/- 2.4 h) and darbepoetin alpha (25.3 +\/- 2.2h).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28168382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        27208431            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26747131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26479890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that EPO\/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27086036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27543111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPO is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem\/progenitor cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        27865586            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of contemporary aspects of EPO relating to chronic liver disease. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919118            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hepatic EPO synthesis is not enhanced in cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26924722            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26838000            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26097591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27081163            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inadequate erythropoietin response may partly explain anemia in anorexia nervosa.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26049959            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26012423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA\/MMP9-mediated proteolytic network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26469975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26995951            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25675872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447159            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage            \u003ca rel=\"nofollow\"\u003e             PMID:                        25628168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25793991            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"Default Title","offer_id":43181816414433,"sku":"BL-1638SG","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-epo-c-6his-bl-2885np","title":"Recombinant Human EPO Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin is produced by our Mammalian expression system and the target gene encoding Ala28-Arg193 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP01588\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin; Epoetin; EPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin (EPO) is a glycoprotein hormone that is principally known for its role in erythropoiesis, where it is responsible for stimulating proliferation and differentiation of erythroid progenitor cells. Erythropoietin is a member of the EPO\/TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. The differentiation of CFU-E (Colony Forming Unit-Erythroid) cells into erythrocytes can only be accomplished in the presence of EPO. Physiological levels of EPO in adult mammals are maintained primarily by the kidneys, whereas levels in fetal or neonatal mammals are maintained by the liver. EPO also can exert various non-hematopoietic activities, including vascularization and proliferation of smooth muscle, neural protection during hypoxia, and stimulation of certain B cells. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19.2 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e30-40 kDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNot tested\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3415           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133170           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2056           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000252723           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29395333            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the implication of alpha-7-nAChR-JAK-2\/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS            \u003ca rel=\"nofollow\"\u003e             PMID:                        29220591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28983059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27853265            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28603097            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28173069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29514032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28553927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27282568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26822707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            age 3 plasma levels of EPO were found related to childhood asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        27434124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28247960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28038963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO dependent regulation pathway of FGF23 gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        29073196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27161360            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        27266727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27981303            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27441662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27190272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +\/- 13.28 h) in comparison to epoetin alpha (8.5 +\/- 2.4 h) and darbepoetin alpha (25.3 +\/- 2.2h).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28168382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        27208431            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26747131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26479890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that EPO\/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27086036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27543111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPO is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem\/progenitor cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        27865586            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of contemporary aspects of EPO relating to chronic liver disease. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919118            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hepatic EPO synthesis is not enhanced in cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26924722            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26838000            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26097591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27081163            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inadequate erythropoietin response may partly explain anemia in anorexia nervosa.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26049959            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26012423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA\/MMP9-mediated proteolytic network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26469975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26995951            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25675872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447159            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage            \u003ca rel=\"nofollow\"\u003e             PMID:                        25628168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25793991            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43911665647841,"sku":"BL-2885NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLQqANU-0AACY-LCoU8Y785.jpg?v=1685850535"},{"product_id":"recombinant-mouse-epo-c-6his-bl-2888np","title":"Recombinant Mouse EPO Protein (C-6His)","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003ch3 class=\"font_9\"\u003e\n\u003cspan\u003eProduct Overview\u003c\/span\u003e\n\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Erythropoietin is produced by our Mammalian expression system and the target gene encoding Ala27-Arg192 is expressed with a 6His tag at the C-terminus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eAccession\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca title=\"Q0VED9\" target=\"_blank\" href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q0VED9\/entry\"\u003eQ0VED9\u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonym\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin; Epoetin; EPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eGene Background\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin (EPO) is a glycoprotein hormone that is principally known for its role in erythropoiesis, where it is responsible for stimulating proliferation and differentiation of erythroid progenitor cells. Erythropoietin is a member of the EPO\/TPO family. It is a secreted, glycosylated cytokine composed of four alpha helical bundles. The differentiation of CFU-E (Colony Forming Unit-Erythroid) cells into erythrocytes can only be accomplished in the presence of EPO. Physiological levels of EPO in adult mammals are maintained primarily by the kidneys, whereas levels in fetal or neonatal mammals are maintained by the liver. EPO also can exert various non-hematopoietic activities, including vascularization and proliferation of smooth muscle, neural protection during hypoxia, and stimulation of certain B cells. Genetic variation in erythropoietin is associated with susceptbility to microvascular complications of diabetes type 2. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMolecular Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19.4 KDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eApmol Mass\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e30-40 KDa, reducing conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eFormulation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by reducing SDS-PAGE. (QC verified)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBiological Activity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiologically active. Please contact us to obtain bioactivity data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAlways centrifuge tubes before opening.Do not mix by vortex or pipetting.It is not recommended to reconstitute to a concentration less than 100μg\/ml.Dissolve the lyophilized protein in distilled water.Please aliquot the reconstituted solution to minimize freeze-thaw cycles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.Reconstituted protein solution can be stored at 2-8°C for 2-7 days.Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eShipping\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe product is shipped at ambient temperature.Upon receipt, store it immediately at the temperature listed below.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUsage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10μg","offer_id":43911665746145,"sku":"BL-2888NP","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CgAKNmLkLR-AKAcyAACNt1BOqC4387.jpg?v=1685850539"},{"product_id":"recombinant-rat-erythropoietin-receptor-epor-protein-his-sumo-his-blc-00033p","title":"Recombinant Rat Erythropoietin Receptor (EPOR) Protein (His-SUMO\u0026His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat Erythropoietin Receptor (EPOR) Protein (His-SUMO\u0026amp;His) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q07303          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpor; Erythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRattus norvegicus (Rat)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u0026amp;C-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eASSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAANSGMGFNYSFSYQLEGESRKSCRLHQAPTVRGSMRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-249aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e39.1 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10116.ENSRNOP00000017369           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Rn\u0026amp;CID=22394\"\u003e            Rn.22394           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIsoform EPOR-F and isoform EPOR-S are expressed in bone marrow, spleen and eythroleukemia cell lines.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998328258785,"sku":"BLC-00033P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007744RAa3-SDS.jpg?v=1690493379"},{"product_id":"recombinant-dog-erythropoietin-receptor-epor-protein-his-gb1-his-blc-00037p","title":"Recombinant Dog Erythropoietin Receptor (EPOR) Protein (His-GB1\u0026His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Dog Erythropoietin Receptor (EPOR) Protein (His-GB1\u0026amp;His) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q2KL21          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPORErythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCanis lupus familiaris (Dog)(Canis familiaris)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-GB1\u0026amp;C-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eASLPKPLDPKFESKAALLAARAPEELLCFTERLEDLVCFWEEAASAGVGPDNYSFFYQLEGEPWKTCSLHQAPTTRGAVRFWCSLPTADTSSFVPLELRATAVSSGALLYRRIIHINEVVLLDPPAGLLARRADEGGHVVLRWLPPPGAPVASLIRYEVNISGSVAGGSQKVEILDGRTECVLSNLRGGTRYTFMVRARMAEPSFGGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-250aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e36.4 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            cfa:484943           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9615.ENSCAFP00000025668           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        18495932            \u003c\/a\u003e  \u003c\/p\u003e\n\u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998330028257,"sku":"BLC-00037P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007744DOg9-SDS.jpg?v=1690493392"},{"product_id":"recombinant-aspergillus-tubingensis-epoxide-hydrolase-protein-his-blc-00352p","title":"Recombinant Aspergillus Tubingensis Epoxide Hydrolase Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Aspergillus Tubingensis Epoxide Hydrolase Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           T2FEN1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eT2FEN1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAspergillus tubingensis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMALAHSNIPSGTTVIPSPFQVHVSDEQIEELQLLVKLSKLAPPTYEGLQQDRKYGITNEWLANAKEAWKSLDWRSAESRINSFPQFTYDIEGLTIHFVALFSERKDAIPIVLLHGWPGSFLEFLPALTSIRDKYSPETLPYHIVIPSLPGFTFSSGPPLDVNFTGVDTARVINKVMLNLGFEDGYVAQGGDIGSRIGRILAVDHESCKAVHLNACYMGKPSNVPDTAITEEDKRALARAQWFGTYGSGYALEHGTRPSTIGNVLSTNPVALLAWIGEKFLDWADEAVPLESILESVSLYWFTETFPRSIYHYRENVPPPKLRQAEDPRWYIRKPFGFSYYPKELVPTPRAWVETTGNLVFWQAHEKGGHFAALERPQDFLNDLTAFCEQVWAGRK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-395aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998370660577,"sku":"BLC-00352P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP4652DPD-SDS.jpg?v=1690494582"},{"product_id":"recombinant-hypsizygus-marmoreus-putative-epoxide-hydrolase-hypma-001463-protein-his-blc-00364p","title":"Recombinant Hypsizygus Marmoreus Putative Epoxide Hydrolase (HYPMA_001463) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Hypsizygus Marmoreus Putative Epoxide Hydrolase (HYPMA_001463) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           A0A369K0H6          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHYPMA_001463\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHypsizygus marmoreus (White beech mushroom) (Agaricus marmoreus)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMSQFNTLPASAVLRPTPFELKIPNDAVDELKLLLKHSKVPPDTYENTQEDRRYGVTTKWIREAKARWENNFDWRAHEAHINSFPHYISPIVDDDGTTYNIHFVALFSQKPDAIPIVLLHGWPGSFLEFLPILDKLRTSYTPATLPYHLVVPSLPGYTFSSPPPVDKDLGLEDVARLFDKLARGLGFENGYVVQGGDIGSIVARIMAATYPSCKAIHINFCIIPEPAGIDSSSLNDLDKQGLARTAEFSRLGSAYALTQATKPGTIGIVLSSNPLALLAWIGEKFLAWNDEDPPLDTILESVTLYWFTDTISRAFYPYRQLFTPGNAGAHSNPIWYINKPFGFSWFPKELGLVPRSWAATTGNLVFFRRHSKGGHFAALECPEVLLKDLEEFVAQVWNAVTLDCAWVSASPVADVNNLGARHLSFLINCAPLRRPQDK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-437aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e54.7 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998372036833,"sku":"BLC-00364P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP4654GSX-SDS.jpg?v=1690494636"},{"product_id":"recombinant-aspergillus-tubingensis-epoxide-hydrolase-protein-his-blc-00412p","title":"Recombinant Aspergillus Tubingensis Epoxide Hydrolase Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Aspergillus Tubingensis Epoxide Hydrolase Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           T2FEN1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eT2FEN1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAspergillus tubingensis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMALAHSNIPSGTTVIPSPFQVHVSDEQIEELQLLVKLSKLAPPTYEGLQQDRKYGITNEWLANAKEAWKSLDWRSAESRINSFPQFTYDIEGLTIHFVALFSERKDAIPIVLLHGWPGSFLEFLPALTSIRDKYSPETLPYHIVIPSLPGFTFSSGPPLDVNFTGVDTARVINKVMLNLGFEDGYVAQGGDIGSRIGRILAVDHESCKAVHLNACYMGKPSNVPDTAITEEDKRALARAQWFGTYGSGYALEHGTRPSTIGNVLSTNPVALLAWIGEKFLDWADEAVPLESILESVSLYWFTETFPRSIYHYRENVPPPKLRQAEDPRWYIRKPFGFSYYPKELVPTPRAWVETTGNLVFWQAHEKGGHFAALERPQDFLNDLTAFCEQVWAGRK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-395aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e46.0 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998378295521,"sku":"BLC-00412P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP4652DPD-SDS.jpg?v=1690494806"},{"product_id":"recombinant-human-erythropoietin-receptor-epor-protein-his-blc-00976p","title":"Recombinant Human Erythropoietin Receptor (EPOR) Protein (His)","description":"\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eProduct Overview\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin Receptor (EPOR) Protein (His) is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e P19235 \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e(EPO-R)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDLVCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPLELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRYEVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPVSLLTPSDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-250aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27.6 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eTarget Details\u003c\/h3\u003e\n\u003ctable width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.; Isoform EPOR-T acts as a dominant-negative receptor of EPOR-mediated signaling.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Single-pass type I membrane protein.; [Isoform EPOR-S]: Secreted. Note=Secreted and located to the cell surface.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\n\u003cdiv\u003e\n\u003cp\u003eHGNC: \u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20124513\"\u003e PMID: 20124513 \u003c\/a\u003e\n\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"100ug","offer_id":45919843483873,"sku":"BLC-00976P","price":240.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-MP007744HU1-SDS.jpg?v=1690496825"},{"product_id":"recombinant-horse-erythropoietin-epo-protein-hfc-blc-01289p","title":"Recombinant Horse Erythropoietin (EPO) Protein (hFc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Horse Erythropoietin (EPO) Protein (hFc) is produced by our Mammalian cell expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q867B1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEquus caballus (Horse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYILEAREAENVTMGCAEGCSFGENVTVPDTKVNFYSWKRMEVEQQAVEVWQGLALLSEAILQGQALLANSSQPSETLRLHVDKAVSSLRSLTSLLRALGAQKEAISPPDAASAAPLRTFAVDTLCKLFRIYSNFLRGKLKLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e47.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eNeuroscience\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ecb:100033849           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9796.ENSECAP00000008707           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Eca\u0026amp;CID=12758\"\u003e            Eca.12758           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998486921441,"sku":"BLC-01289P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-MP007743HO-SDS.jpg?v=1690497972"},{"product_id":"recombinant-mouse-erythropoietin-receptor-epor-protein-his-blc-01359p","title":"Recombinant Mouse Erythropoietin Receptor (EPOR) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Erythropoietin Receptor (EPOR) Protein (His) is produced by our Baculovirus expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P14753          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpor; Erythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMus musculus (Mouse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBaculovirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAASSGMDFNYSFSYQLEGESRKSCSLHQAPTVRGSVRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-249aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e[Isoform EPOR-F]: Cell membrane; Single-pass type I membrane protein.; [Isoform EPOR-S]: Secreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:13857           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000006397           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27998978            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            A solution NMR study of the mouse erythropoietin receptor (mEpoR) comprising the transmembrane domain and the juxtamembrane regions reconstituted in dodecylphosphocholine (DPC) micelles.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26316120            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            loss of function results in defective macrophage clearance of apoptotic cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26872696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data indicate that EpoR signaling is associated with cardiac remodeling following chronic iron deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25715089            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We propose that the CID-dependent dimerization system combined with the EpoR intracellular domain and the Gata1 gene regulatory region generates a novel peroral strategy for the treatment of anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25790231            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles            \u003ca rel=\"nofollow\"\u003e             PMID:                        25418301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR and its activity are downstream effectors of Klotho enabling it to function as a cytoprotective protein against oxidative injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23636173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of EPOR in rod photoreceptors, Muller cells, and amacrine, horizontal, and ganglion cells of the peripheral retina is not required for the maturation, function, and survival of these cells in aging tissue.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24644405            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data from knockout mice suggest that adipose tissue-specific disruption of EPO receptor does not alter adipose tissue expansion, adipocyte morphology, insulin resistance, inflammation, or angiogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23885016            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the EPO-EPOR system may play a role in glucose metabolism within adipocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23313788            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR regulates transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO-dependent erythroblast formation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22808010            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression of EPOR decreased with the development of renal cortex            \u003ca rel=\"nofollow\"\u003e             PMID:                        22844537            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            enhanced activation of signaling pathways downstream of the EPO-receptor, indicate that SH2B1 is a negative regulator of EPO signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22669948            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO\/EPOR signaling from astrocyte to oligodendrocyte progenitor cells (OPC) prevents OPC damage under hypoxic\/reoxygenation conditions.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21833990            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Postmortem neural precursor cells differentiate mostly in self-renewable neurons, show activation, and express both erythropoietin (EPO) and its receptor (EPO-R).            \u003ca rel=\"nofollow\"\u003e             PMID:                        21324364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expressed in both non-wounded and wounded skin tissue as well as in fibroblasts and keratinocytes            \u003ca rel=\"nofollow\"\u003e             PMID:                        21894148            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gata4 or Sp1 may limit the accessibility of the EpoR for binding of erythropoiesis-stimulating agents.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21029371            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Mice with transgenic expression of a constitutively active erythropoietin receptor isoform in pyramidal neurons of cortex and hippocampus exhibit enhancement of spatial learning, cognitive flexibility, social memory, and attentional capacities.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21527022            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Epo\/EpoR complex plays a critical role in the adhesion and migration of rat fibroblasts, and its functional inactivation is associated with PLC-gammal-dependent reduction of cell-matrix adhesion and this also affects cell migration.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21360263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic ablation promotes Salmonella elimination            \u003ca rel=\"nofollow\"\u003e             PMID:                        21256055            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data provide evidence of a role for nitric oxide in erythropoietin activity in brain and suggest links between NO production, EpoR expression, and Epo signaling in neuroprotection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20806411            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The phosphorylation of EpoR at Y479 is required for oncogenic signaling of JAK2 V617F mutant and that targeted disruption of this pathway has therapeutic utility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21255641            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ubiquitination of the EpoR critically controls both receptor down-regulation and downstream signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21183685            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Darbepoetin stimulates multiple cardioprotective mechanisms in infarcted myocardium to improve cardiac function independent of erythropoietin receptor-common beta-chain heteroreceptor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20649603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            regional specific up-regulation of EPOR at an early stage after MPTP stimulus may represent a pro-survival mechanism against neurotoxin injury in Parkinsonian model            \u003ca rel=\"nofollow\"\u003e             PMID:                        19537929            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            rapid ligand depletion \u0026amp; replenishment of cell surface receptor are characteristic of EpoR; Epo-EpoR complexes \u0026amp; EpoR activation integrated over time correspond linearly to ligand input; relation depends on EpoR turnover            \u003ca rel=\"nofollow\"\u003e             PMID:                        20488988            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the presence of EpoR is required to activate oncogenic signaling via the JAK2 mutant and STAT5, its interacting ability is a target for the treatment of these hematopoietic diseases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20028972            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor            \u003ca rel=\"nofollow\"\u003e             PMID:                        11779507            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Epo receptor cytoplasmic domain conformation is essential for the initiation of signal transduction            \u003ca rel=\"nofollow\"\u003e             PMID:                        11997394            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            developmental defect of PrlR(-\/-) mammary epithelium is rescued by an exogenously expressed chimeric receptor (prl-EpoR) containing the PrlR extracellular domain joined to the EpoR transmembrane and intracellular domains            \u003ca rel=\"nofollow\"\u003e             PMID:                        12381781            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            demonstration of an essential role for Src pathway in regulating growth, proliferation, and cooperation with Epo-Receptor downstream from Kit            \u003ca rel=\"nofollow\"\u003e             PMID:                        12486028            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            C-hexosylation of the WSAWS motif did not play a role in the correct intracellular transport of sEPOR            \u003ca rel=\"nofollow\"\u003e             PMID:                        12859190            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the function of JAK2-coupled but phosphotyrosine-null Epo form appears to be attenuated in several contexts and to be assisted in vivo by compensatory mechanisms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12869513            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the Epo receptor Tyr-343 Stat5 pathway has a role in proliferative co-signaling with kit            \u003ca rel=\"nofollow\"\u003e             PMID:                        12909618            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR can be activated to different extents by homodimeric gp55 proteins, depending on the conformation of the gp55 protein dimer in the TM region            \u003ca rel=\"nofollow\"\u003e             PMID:                        12930840            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            erythropoietin receptor transmembrane segments self-interaction depends on a membrane-spanning leucine zipper            \u003ca rel=\"nofollow\"\u003e             PMID:                        14602718            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that the activity of the erythropoietin receptor is determined by the helical periodicity or orientation of the transmembrane and cytosolic domains.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14636581            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results elucidate a previously unrecognized hematopoietic cell survival pathway elicited by the EPOR, that requires Stat5 and is serum independent.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14662339            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a functional EPO-R may be necessary and sufficient for TPO to exert its mitogenic effects on erythroid cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15102474            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Knockout mice exhibit normal erythrocyte maturation, so receptor is not resquired for erythropoiesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        15456912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TM-JM junction of EpoR forms an N-terminal helix cap required for function            \u003ca rel=\"nofollow\"\u003e             PMID:                        15657048            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Friend virus activates both sf-STK and the EPOR to cause deregulated erythroid proliferation and differentiation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16174761            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In knockout mice, epoietein induced reticulocyte and erythroblast maturation were attenuated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16332976            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of gene expression induced by erythropoietin receptor structural variants            \u003ca rel=\"nofollow\"\u003e             PMID:                        16380376            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            model of the active and inactive conformations of the Epo receptor            \u003ca rel=\"nofollow\"\u003e             PMID:                        16414957            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The classical EPOR is essential for EPO action during embryonic neurogenes \u0026amp; is important for adult neurogenesis and for migration of regenerating neurons during post-injury recovery.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16436614            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Stress erythropoiesis during anemia is rescued to wild type levels upon the selective restoration of an EpoR-phosphotyrosine-Stat5-binding site signaling axis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16511603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The vascular EpoR system plays an important role in angiogenesis in response to hindlimb ischemia through upregulation of the vascular endothelial growth factor\/VEGF receptor system.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17293480            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In mice expressing an EpoR allele, compromised erythropoietin-induced podocalyxin expression correlated with enucleated red cells in bone marrow.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17403918            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hypoxic downregulation of sEpoR is required for adequate ventilatory acclimatization to hypoxia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17584830            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998494884065,"sku":"BLC-01359P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-BP007744MO1-SDS.jpg?v=1690498192"},{"product_id":"recombinant-horse-erythropoietin-epo-protein-his-myc-blc-01366p","title":"Recombinant Horse Erythropoietin (EPO) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Horse Erythropoietin (EPO) Protein (His\u0026amp;Myc) is produced by our Baculovirus expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q867B1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEquus caballus (Horse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBaculovirus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYILEAREAENVTMGCAEGCSFGENVTVPDTKVNFYSWKRMEVEQQAVEVWQGLALLSEAILQGQALLANSSQPSETLRLHVDKAVSSLRSLTSLLRALGAQKEAISPPDAASAAPLRTFAVDTLCKLFRIYSNFLRGKLKLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e22.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ecb:100033849           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9796.ENSECAP00000008707           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Eca\u0026amp;CID=12758\"\u003e            Eca.12758           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998495473889,"sku":"BLC-01366P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-BP007743HO-SDS.jpg?v=1690498212"},{"product_id":"recombinant-horse-erythropoietin-epo-protein-his-blc-01457p","title":"Recombinant Horse Erythropoietin (EPO) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Horse Erythropoietin (EPO) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q867B1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEquus caballus (Horse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYILEAREAENVTMGCAEGCSFGENVTVPDTKVNFYSWKRMEVEQQAVEVWQGLALLSEAILQGQALLANSSQPSETLRLHVDKAVSSLRSLTSLLRALGAQKEAISPPDAASAAPLRTFAVDTLCKLFRIYSNFLRGKLKLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e20.4 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ecb:100033849           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9796.ENSECAP00000008707           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Eca\u0026amp;CID=12758\"\u003e            Eca.12758           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998504681697,"sku":"BLC-01457P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP007743HO-SDS.jpg?v=1690498499"},{"product_id":"recombinant-pig-erythropoietin-epo-protein-his-b2m-blc-02930p","title":"Recombinant Pig Erythropoietin (EPO) Protein (His-B2M)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Pig Erythropoietin (EPO) Protein (His-B2M) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P49157          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSus scrofa (Pig)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-B2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYILEAKEGENATMGCAESCSFSENITVPDTKVNFYAWKRMEVQQQAMEVWQGLALLSEAILQGQALLANSSQPSEALQLHVDKAVSGLRSLTSLLRALGAQKEAIPLPDASPSSATPLRTFAVDTLCKLFRNYSNFLRGKLTLYTGEACRRRDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-194aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e32.6kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ssc:397249           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9823.ENSSSCP00000008194           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        19908127            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Pyruvate-fortified cardioplegia evokes myocardial erythropoietin signaling in swine undergoing cardiopulmonary bypass.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19767525            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998651547873,"sku":"BLC-02930P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007743PI-SDS.jpg?v=1690503194"},{"product_id":"recombinant-pig-erythropoietin-epo-protein-his-blc-03040p","title":"Recombinant Pig Erythropoietin (EPO) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Pig Erythropoietin (EPO) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P49157          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSus scrofa (Pig)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYILEAKEGENATMGCAESCSFSENITVPDTKVNFYAWKRMEVQQQAMEVWQGLALLSEAILQGQALLANSSQPSEALQLHVDKAVSGLRSLTSLLRALGAQKEAIPLPDASPSSATPLRTFAVDTLCKLFRNYSNFLRGKLTLYTGEACRRRDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-194aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e20.6kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ssc:397249           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9823.ENSSSCP00000008194           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        19908127            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            Pyruvate-fortified cardioplegia evokes myocardial erythropoietin signaling in swine undergoing cardiopulmonary bypass.            \u003ca rel=\"nofollow\"\u003e             PMID:                        19767525            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998661083361,"sku":"BLC-03040P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP007743PI-SDS.jpg?v=1690503548"},{"product_id":"recombinant-human-epoxide-hydrolase-1-ephx1-protein-his-sumo-blc-03161p","title":"Recombinant Human Epoxide Hydrolase 1 (EPHX1) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Epoxide Hydrolase 1 (EPHX1) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P07099          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPHX1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPHX 1; EPHX; Ephx1; EPOX; Epoxide hydratase; Epoxide hydrolase 1; Epoxide hydrolase 1 microsomal (xenobiotic); Epoxide hydroxylase 1; Epoxide hydroxylase 1 microsomal (xenobiotic); HYEP_HUMAN; HYL1; MEH; Microsomal epoxide hydrolase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMWLEILLTSVLGFAIYWFISRDKEETLPLEDGWWGPGTRSAAREDDSIRPFKVETSDEEIHDLHQRIDKFRFTPPLEDSCFHYGFNSNYLKKVISYWRNEFDWKKQVEILNRYPHFKTKIEGLDIHFIHVKPPQLPAGHTPKPLLMVHGWPGSFYEFYKIIPLLTDPKNHGLSDEHVFEVICPSIPGYGFSEASSKKGFNSVATARIFYKLMLRLGFQEFYIQGGDWGSLICTNMAQLVPSHVKGLHLNMALVLSNFSTLTLLLGQRFGRFLGLTERDVELLYPVKEKVFYSLMRESGYMHIQCTKPDTVGSALNDSPVGLAAYILEKFSTWTNTEFRYLEDGGLERKFSLDDLLTNVMLYWTTGTIISSQRFYKENLGQGWMTQKHERMKVYVPTGFSAFPFELLHTPEKWVRFKYPKLISYSYMVRGGHFAAFEEPELLAQDIRKFLSVLERQ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-455aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e68.9kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMetabolism\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiotransformation enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to less reactive and more water soluble dihydrodiols by the trans addition of water. Plays a role in the metabolism of endogenous lipids such as epoxide-containing fatty acids. Metabolizes the abundant endocannabinoid 2-arachidonoylglycerol (2-AG) to free arachidonic acid (AA) and glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMicrosome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePeptidase S33 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3401           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            132810           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2052           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000272167           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27256986            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            EPHX1 variants were significantly associated with higher metabolic ratio of carbamazepine            \u003ca rel=\"nofollow\"\u003e             PMID:                        27276192            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphisms in EPHX1, GSTP1, SERPINE2, and TGFB1 contributing to the quantitative traits of chronic obstructive pulmonary disease in Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27193053            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study showed that polymorphisms of EPHX1 and VKORC1L1 could be determinants of stable warfarin doses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29054760            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Tyr113His T\/C variant of rs1051740 and very slow phenotype alters EPHX1, miR-26b-5p and miR-1207-5p expression, and contributes towards low blood iron levels and low birthweights.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28789952            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Structural characterization of human microsomal epoxide hydrolase by combined homology modeling, molecular dynamics simulations, and molecular docking calculations has been reported.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28120429            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Y113H polymorphism in EPHX1 gene contributed to increased susceptibility to COPD in the Kazakhstan population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28464990            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 polymorphisms were not associated with sporadic colorectal neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28018104            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study demonstrated that two SNPs might play roles in the process of nicotine metabolism and abstinence, rs1051740 being more important; and EPHX SNPs (rs1051740 and rs2234922) are associated with the effectiveness of Nicotine Replacement Therapy .            \u003ca rel=\"nofollow\"\u003e             PMID:                        27783326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No association was found between EPHX1 and COPD; however, a minor effect of EPHX1 on COPD risk was not completely excluded.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27173271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The SCN1A IVS5-91G\u0026gt;A SNP is associated with susceptibility to epilepsy. SNPs in EPHX1 gene are influencing CBZ metabolism and disposition            \u003ca rel=\"nofollow\"\u003e             PMID:                        26555147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In conclusion, GSTs, EPHX1, and XPD are potential genetic factors for arsenic-induced skin cancers. The roles of these genes for arsenic-induced skin carcinogenesis need to be further evaluated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26295053            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the EPHX1 Tyr113His polymorphism may be a risk factor for lung cancer in Asians, whereas it may be a decreased risk factor among Caucasians. However, this polymorphism was not found to be associated with breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25222243            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            To be poly(ADP-ribose)polymerase-1 (PARP-1) bound to the EPHX1 proximal promoter.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25992604            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Polymorphism in the EPHX1 gene may have a significant role in differential responses to treatment with N-acetylcysteine in patients with COPD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25999707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review and meta-analysis suggests that EPHX1 Tyr113His polymorphism may be a risk factor for Head and Neck Cancer, while the EPHX1 His139Arg polymorphism has no association with Head and Neck Cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25923690            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studies suggest that the presence of microsomal epoxide hydrolase 1 (EPHX1) single nucleotide polymorphisms (SNPs) may significantly affect the risk of lung, upper aerodigestive tract, breast, bladder, and ovarian carcinomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26216302            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the genetic associations exist between mEH polymorphisms and lung cancer susceptibility in Asian populations            \u003ca rel=\"nofollow\"\u003e             PMID:                        25312477            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results demonstrate that 2-AG is an endogenous substrate for EPHX1, a potential role of EPHX1 in the endocannabinoid signaling and a new AA biosynthetic pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24958911            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 rs2292566 polymorphism may affect the maintenance dose of warfarin in Caucasians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25629049            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            His\/His genotype of EPHX1 Tyr113His polymorphism is a risk factor for developing caner for Asian and mixed population, while no evidence was found for the association between the EPHX1 His139Arg polymorphism and increased cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25261893            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 Tyr113His and His139Arg polymorphism are not associated with esophageal cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25714851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis suggests that EPHX1 Tyr113His polymorphism contributes to HCC risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26065263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No clear effect is evident for EPHX1 polymorphisms for different radon concentrations on the risk of lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24852519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Review\/Meta-analysis: suggest p.Tyr113His and p.His139Arg polymorphisms in EPHX1 may not be associated with esophageal cancer development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24803829            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study provides direct evidence that methylation plays an important role in PCOS and demonstrates a novel role for EPHX1 in female reproduction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24505354            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Meta-analysis showed that the Tyr113His polymorphism was a stronger power trend towards risk for esophageal cancer using a recessive model            \u003ca rel=\"nofollow\"\u003e             PMID:                        24615030            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The association of EPHX1 polymorphism with the HELLP syndrome and eclampsia may hint to EPHX being a further key player in the pathogenesis of preeclampsia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24013430            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that Exons 3 and 4 polymorphisms of the mEH gene may contribute to lung cancer susceptibility through disturbed antioxidant balance.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23928928            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The C allele and C-G diplotype of EPHX1 may play important roles in increasing the risk of CBZ-SJS\/toxic epidermal necrolysis development of epilepsy in Chinese Han patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24861996            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Chinese epilepsy patients with variant EPHX1 c.416A\u0026gt;G genotype have higher plasma carbamazepine concentrations compared to those with the wild type genotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24125961            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No evidence of an association of EPHX1 Tyr113His or His139Arg polymorphisms with risk for development of esophageal cancer. [Meta-analysis]            \u003ca rel=\"nofollow\"\u003e             PMID:                        24222229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 genetic polymorphisms were not associated with the risk of HCC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23955801            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The study showed that microsomal epoxide hydrolase exon 3 113Tyr-139Arg was associated with gastric cancer in presence of H. pylori, though in its absence, it appeared to be protective.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23580125            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sp1 and Sp3 are functionally involved as transcriptional integrators regulating the basal expression of the derived microsomal epoxide hydrolase E1b variant transcript.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24315822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genotype frequencies for EPHX1 polymorphisms did not show any correlation with lymphoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23651475            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis suggests that EPHX1 His139Arg polymorphism is associated with decreased risk of esophageal cancer in Caucasians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23681797            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is substantial evidence that mEH polymorphisms interact synergistically with other genes and the environment to modulate risk of HCC            \u003ca rel=\"nofollow\"\u003e             PMID:                        23451147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that benzene exposure may be associated with hypermethylation in ERCC3, and that genetic variants in EPHX1 may play an important role in epigenetic changes and hematotoxicity among benzene-exposed workers            \u003ca rel=\"nofollow\"\u003e             PMID:                        23797950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This is the first report that examined HIF1A polymorphisms in chronic obstructive pulmonary disease and demonstrated a possible role of HIF-1alpha in COPD, as well as GSTP1 and EPHX1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21651746            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 transcript, termed E1-b', drives EPHX1 expression primarily in the ovary.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23564882            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 gene polymorphisms and haplotypes are associated with an increased risk for alcoholism in the Kota Indian population            \u003ca rel=\"nofollow\"\u003e             PMID:                        22257321            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            minor Tyr113 allele of mEPHX1 polymorphism had a higher risk of type 2 diabetes mellitus            \u003ca rel=\"nofollow\"\u003e             PMID:                        22555758            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Microsomal epoxide hydrolase 1 T113C polymorphism is associated with lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23378225            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the maternal EPHX1 rs1051740 genotype (RR = 3.26, P = .01) was associated with medulloblastoma risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22994552            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Meta-analyses of available data supported the concept of EPHX1 A139G polymorphism as a genetic susceptibility factor for lung cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        23055191            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 gene polymorphisms and haplotypes were not involved in the susceptibility to oral cancer in South Indian subjects.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21453055            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 Tyr113His polymorphism may be not associated with CRC development            \u003ca rel=\"nofollow\"\u003e             PMID:                        22928041            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study analyzed the association between four SNPs in the EPHX1 and EPHX2 and the risk of oligozoospermia and asthenospermia; rs1051740, rs2234922 and rs751141 were not associated with oligozoospermia and asthenospermia and rs1042064 was a protective factor in idiopathic male infertility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22986331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            microsomal epoxide hydrolase polymorphism is associated with chromosomal instability of 1,3-butadiene exposed workers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22156006            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998672879841,"sku":"BLC-03161P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007734HU-SDS.jpg?v=1690503923"},{"product_id":"recombinant-human-epoxide-hydrolase-1-ephx1-protein-his-blc-03451p","title":"Recombinant Human Epoxide Hydrolase 1 (EPHX1) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Epoxide Hydrolase 1 (EPHX1) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P07099          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPHX1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPHX 1; EPHX; Ephx1; EPOX; Epoxide hydratase; Epoxide hydrolase 1; Epoxide hydrolase 1 microsomal (xenobiotic); Epoxide hydroxylase 1; Epoxide hydroxylase 1 microsomal (xenobiotic); HYEP_HUMAN; HYL1; MEH; Microsomal epoxide hydrolase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMWLEILLTSVLGFAIYWFISRDKEETLPLEDGWWGPGTRSAAREDDSIRPFKVETSDEEIHDLHQRIDKFRFTPPLEDSCFHYGFNSNYLKKVISYWRNEFDWKKQVEILNRYPHFKTKIEGLDIHFIHVKPPQLPAGHTPKPLLMVHGWPGSFYEFYKIIPLLTDPKNHGLSDEHVFEVICPSIPGYGFSEASSKKGFNSVATARIFYKLMLRLGFQEFYIQGGDWGSLICTNMAQLVPSHVKGLHLNMALVLSNFSTLTLLLGQRFGRFLGLTERDVELLYPVKEKVFYSLMRESGYMHIQCTKPDTVGSALNDSPVGLAAYILEKFSTWTNTEFRYLEDGGLERKFSLDDLLTNVMLYWTTGTIISSQRFYKENLGQGWMTQKHERMKVYVPTGFSAFPFELLHTPEKWVRFKYPKLISYSYMVRGGHFAAFEEPELLAQDIRKFLSVLERQ\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1-455aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e56.9 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell Biology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBiotransformation enzyme that catalyzes the hydrolysis of arene and aliphatic epoxides to less reactive and more water soluble dihydrodiols by the trans addition of water. Plays a role in the metabolism of endogenous lipids such as epoxide-containing fatty acids. Metabolizes the abundant endocannabinoid 2-arachidonoylglycerol (2-AG) to free arachidonic acid (AA) and glycerol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMicrosome membrane; Single-pass type III membrane protein. Endoplasmic reticulum membrane; Single-pass type III membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePeptidase S33 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3401           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            132810           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2052           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000272167           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27256986            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            EPHX1 variants were significantly associated with higher metabolic ratio of carbamazepine            \u003ca rel=\"nofollow\"\u003e             PMID:                        27276192            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Single nucleotide polymorphisms in EPHX1, GSTP1, SERPINE2, and TGFB1 contributing to the quantitative traits of chronic obstructive pulmonary disease in Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27193053            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study showed that polymorphisms of EPHX1 and VKORC1L1 could be determinants of stable warfarin doses.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29054760            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Tyr113His T\/C variant of rs1051740 and very slow phenotype alters EPHX1, miR-26b-5p and miR-1207-5p expression, and contributes towards low blood iron levels and low birthweights.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28789952            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Structural characterization of human microsomal epoxide hydrolase by combined homology modeling, molecular dynamics simulations, and molecular docking calculations has been reported.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28120429            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Y113H polymorphism in EPHX1 gene contributed to increased susceptibility to COPD in the Kazakhstan population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28464990            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 polymorphisms were not associated with sporadic colorectal neoplasms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28018104            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study demonstrated that two SNPs might play roles in the process of nicotine metabolism and abstinence, rs1051740 being more important; and EPHX SNPs (rs1051740 and rs2234922) are associated with the effectiveness of Nicotine Replacement Therapy .            \u003ca rel=\"nofollow\"\u003e             PMID:                        27783326            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No association was found between EPHX1 and COPD; however, a minor effect of EPHX1 on COPD risk was not completely excluded.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27173271            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The SCN1A IVS5-91G\u0026gt;A SNP is associated with susceptibility to epilepsy. SNPs in EPHX1 gene are influencing CBZ metabolism and disposition            \u003ca rel=\"nofollow\"\u003e             PMID:                        26555147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In conclusion, GSTs, EPHX1, and XPD are potential genetic factors for arsenic-induced skin cancers. The roles of these genes for arsenic-induced skin carcinogenesis need to be further evaluated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26295053            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the EPHX1 Tyr113His polymorphism may be a risk factor for lung cancer in Asians, whereas it may be a decreased risk factor among Caucasians. However, this polymorphism was not found to be associated with breast cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25222243            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            To be poly(ADP-ribose)polymerase-1 (PARP-1) bound to the EPHX1 proximal promoter.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25992604            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Polymorphism in the EPHX1 gene may have a significant role in differential responses to treatment with N-acetylcysteine in patients with COPD.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25999707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review and meta-analysis suggests that EPHX1 Tyr113His polymorphism may be a risk factor for Head and Neck Cancer, while the EPHX1 His139Arg polymorphism has no association with Head and Neck Cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25923690            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Studies suggest that the presence of microsomal epoxide hydrolase 1 (EPHX1) single nucleotide polymorphisms (SNPs) may significantly affect the risk of lung, upper aerodigestive tract, breast, bladder, and ovarian carcinomas.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26216302            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the genetic associations exist between mEH polymorphisms and lung cancer susceptibility in Asian populations            \u003ca rel=\"nofollow\"\u003e             PMID:                        25312477            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results demonstrate that 2-AG is an endogenous substrate for EPHX1, a potential role of EPHX1 in the endocannabinoid signaling and a new AA biosynthetic pathway.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24958911            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 rs2292566 polymorphism may affect the maintenance dose of warfarin in Caucasians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25629049            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            His\/His genotype of EPHX1 Tyr113His polymorphism is a risk factor for developing caner for Asian and mixed population, while no evidence was found for the association between the EPHX1 His139Arg polymorphism and increased cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25261893            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 Tyr113His and His139Arg polymorphism are not associated with esophageal cancer risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25714851            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis suggests that EPHX1 Tyr113His polymorphism contributes to HCC risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26065263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No clear effect is evident for EPHX1 polymorphisms for different radon concentrations on the risk of lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24852519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Review\/Meta-analysis: suggest p.Tyr113His and p.His139Arg polymorphisms in EPHX1 may not be associated with esophageal cancer development.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24803829            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This study provides direct evidence that methylation plays an important role in PCOS and demonstrates a novel role for EPHX1 in female reproduction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24505354            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Meta-analysis showed that the Tyr113His polymorphism was a stronger power trend towards risk for esophageal cancer using a recessive model            \u003ca rel=\"nofollow\"\u003e             PMID:                        24615030            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The association of EPHX1 polymorphism with the HELLP syndrome and eclampsia may hint to EPHX being a further key player in the pathogenesis of preeclampsia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24013430            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Results suggest that Exons 3 and 4 polymorphisms of the mEH gene may contribute to lung cancer susceptibility through disturbed antioxidant balance.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23928928            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The C allele and C-G diplotype of EPHX1 may play important roles in increasing the risk of CBZ-SJS\/toxic epidermal necrolysis development of epilepsy in Chinese Han patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24861996            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Chinese epilepsy patients with variant EPHX1 c.416A\u0026gt;G genotype have higher plasma carbamazepine concentrations compared to those with the wild type genotype.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24125961            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            No evidence of an association of EPHX1 Tyr113His or His139Arg polymorphisms with risk for development of esophageal cancer. [Meta-analysis]            \u003ca rel=\"nofollow\"\u003e             PMID:                        24222229            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 genetic polymorphisms were not associated with the risk of HCC.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23955801            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The study showed that microsomal epoxide hydrolase exon 3 113Tyr-139Arg was associated with gastric cancer in presence of H. pylori, though in its absence, it appeared to be protective.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23580125            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Sp1 and Sp3 are functionally involved as transcriptional integrators regulating the basal expression of the derived microsomal epoxide hydrolase E1b variant transcript.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24315822            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Genotype frequencies for EPHX1 polymorphisms did not show any correlation with lymphoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23651475            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This meta-analysis suggests that EPHX1 His139Arg polymorphism is associated with decreased risk of esophageal cancer in Caucasians.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23681797            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            There is substantial evidence that mEH polymorphisms interact synergistically with other genes and the environment to modulate risk of HCC            \u003ca rel=\"nofollow\"\u003e             PMID:                        23451147            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that benzene exposure may be associated with hypermethylation in ERCC3, and that genetic variants in EPHX1 may play an important role in epigenetic changes and hematotoxicity among benzene-exposed workers            \u003ca rel=\"nofollow\"\u003e             PMID:                        23797950            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This is the first report that examined HIF1A polymorphisms in chronic obstructive pulmonary disease and demonstrated a possible role of HIF-1alpha in COPD, as well as GSTP1 and EPHX1.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21651746            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 transcript, termed E1-b', drives EPHX1 expression primarily in the ovary.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23564882            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 gene polymorphisms and haplotypes are associated with an increased risk for alcoholism in the Kota Indian population            \u003ca rel=\"nofollow\"\u003e             PMID:                        22257321            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            minor Tyr113 allele of mEPHX1 polymorphism had a higher risk of type 2 diabetes mellitus            \u003ca rel=\"nofollow\"\u003e             PMID:                        22555758            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Microsomal epoxide hydrolase 1 T113C polymorphism is associated with lung cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23378225            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the maternal EPHX1 rs1051740 genotype (RR = 3.26, P = .01) was associated with medulloblastoma risk.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22994552            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Meta-analyses of available data supported the concept of EPHX1 A139G polymorphism as a genetic susceptibility factor for lung cancer            \u003ca rel=\"nofollow\"\u003e             PMID:                        23055191            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 gene polymorphisms and haplotypes were not involved in the susceptibility to oral cancer in South Indian subjects.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21453055            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPHX1 Tyr113His polymorphism may be not associated with CRC development            \u003ca rel=\"nofollow\"\u003e             PMID:                        22928041            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Study analyzed the association between four SNPs in the EPHX1 and EPHX2 and the risk of oligozoospermia and asthenospermia; rs1051740, rs2234922 and rs751141 were not associated with oligozoospermia and asthenospermia and rs1042064 was a protective factor in idiopathic male infertility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22986331            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            microsomal epoxide hydrolase polymorphism is associated with chromosomal instability of 1,3-butadiene exposed workers.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22156006            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998698143969,"sku":"BLC-03451P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007734HUa0-SDS.jpg?v=1690504813"},{"product_id":"recombinant-treponema-pallidum-uncharacterized-protein-tp-0608-tp-0608-protein-his-myc-blc-03474p","title":"Recombinant Treponema Pallidum Uncharacterized Protein Tp_0608 (TP_0608) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Treponema Pallidum Uncharacterized Protein Tp_0608 (TP_0608) Protein (His\u0026amp;Myc) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           O83617          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP_0608\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTP_0608; Uncharacterized protein TP_0608\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTreponema pallidum (strain Nichols)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eQGTDPSVGAQASAGDGGMMTVEQAYLNSAEGVVIKEMVESRGHDSKVLALQYIQEALEGGRGSDDLQEALSRLATAGLFRVIREQGRVINDFPDIRLRACELLARLPSARTKDALIQVMCADREPSVVRAAVKSLGEVGINEQDETTATIGWISRKFSAINPTGSLALEILNTYERLAPTVRDRRAVVESIMDIAADGRYAAAVRARALEVVKGVVSGGK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e77-296aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e30.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            tpa:TP_0608           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998701420769,"sku":"BLC-03474P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP528172TPR1-1.jpg?v=1690566985"},{"product_id":"recombinant-horse-erythropoietin-epo-protein-his-sumo-blc-03816p","title":"Recombinant Horse Erythropoietin (EPO) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Horse Erythropoietin (EPO) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q867B1          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEquus caballus (Horse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYILEAREAENVTMGCAEGCSFGENVTVPDTKVNFYSWKRMEVEQQAVEVWQGLALLSEAILQGQALLANSSQPSETLRLHVDKAVSSLRSLTSLLRALGAQKEAISPPDAASAAPLRTFAVDTLCKLFRIYSNFLRGKLKLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e34.3kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            ecb:100033849           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9796.ENSECAP00000008707           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Eca\u0026amp;CID=12758\"\u003e            Eca.12758           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998751621345,"sku":"BLC-03816P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007743HO-SDS.jpg?v=1690561807"},{"product_id":"recombinant-cynomolgus-monkey-erythropoietin-epo-protein-his-sumo-blc-03924p","title":"Recombinant Cynomolgus Monkey Erythropoietin (EPO) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Cynomolgus Monkey Erythropoietin (EPO) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P07865          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMacaca fascicularis (Crab-eating macaque) (Cynomolgus monkey)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYLLEAKEAENVTMGCSESCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQAVLANSSQPFEPLQLHMDKAISGLRSITTLLRALGAQEAISLPDAASAAPLRTITADTFCKLFRVYSNFLRGKLKLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e34.2kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Mfa\u0026amp;CID=5395\"\u003e            Mfa.5395           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eProduced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998779113697,"sku":"BLC-03924P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007743MOV-SDS.jpg?v=1690506302"},{"product_id":"recombinant-dog-erythropoietin-receptor-epor-protein-his-blc-04840p","title":"Recombinant Dog Erythropoietin Receptor (EPOR) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Dog Erythropoietin Receptor (EPOR) Protein (His) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q2KL21          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPORErythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCanis lupus familiaris (Dog)(Canis familiaris)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eASLPKPLDPKFESKAALLAARAPEELLCFTERLEDLVCFWEEAASAGVGPDNYSFFYQLEGEPWKTCSLHQAPTTRGAVRFWCSLPTADTSSFVPLELRATAVSSGALLYRRIIHINEVVLLDPPAGLLARRADEGGHVVLRWLPPPGAPVASLIRYEVNISGSVAGGSQKVEILDGRTECVLSNLRGGTRYTFMVRARMAEPSFGGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-250aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            cfa:484943           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9615.ENSCAFP00000025668           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        18495932            \u003c\/a\u003e  \u003c\/p\u003e\n\u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998862803169,"sku":"BLC-04840P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007744DO-SDS.jpg?v=1690509228"},{"product_id":"recombinant-zebrafish-erythropoietin-epo-protein-his-blc-04923p","title":"Recombinant Zebrafish Erythropoietin (EPO) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Zebrafish Erythropoietin (EPO) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q2XNF5          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eepo; Erythropoietin; Erythropoietin-L2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eDanio rerio(Zebrafish)(Brachydanio rerio)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSPLRPICDLRVLDHFIKEAWDAEAAMRTCKDDCSIATNVTVPLTRVDFEVWEAMNIEEQAQEVQSGLHMLNEAIGSLQISNQTEVLQSHIDASIRNIASIRQVLRSLSIPEYVPPTSSGEDKETQKISSISELFQVHVNFLRGKARLLLANAPVCRQGVS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e24-183aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e21.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            dre:100004455           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            7955.ENSDARP00000100433           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        17706649            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            characterization of zebrafish epo and epor demonstrates the conservation of an ancient program that ensures proper red blood cell numbers during normal homeostasis and under hypoxic conditions            \u003ca rel=\"nofollow\"\u003e             PMID:                        17579187            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998871027937,"sku":"BLC-04923P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007743DIL-SDS.jpg?v=1690509531"},{"product_id":"recombinant-cynomolgus-monkey-erythropoietin-epo-protein-his-myc-blc-05091p","title":"Recombinant Cynomolgus Monkey Erythropoietin (EPO) Protein (His-Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Cynomolgus Monkey Erythropoietin (EPO) Protein (His-Myc) is produced by our Mammalian cell expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P07865          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMacaca fascicularis (Crab-eating macaque) (Cynomolgus monkey)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYLLEAKEAENVTMGCSESCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQAVLANSSQPFEPLQLHMDKAISGLRSITTLLRALGAQEAISLPDAASAAPLRTITADTFCKLFRVYSNFLRGKLKLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e22.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Mfa\u0026amp;CID=5395\"\u003e            Mfa.5395           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eProduced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998891147489,"sku":"BLC-05091P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-MP007743MOV-SDS.jpg?v=1690510122"},{"product_id":"recombinant-ralstonia-pickettii-poly-phb-depolymerase-protein-his-blc-05169p","title":"Recombinant Ralstonia Pickettii Poly (PHB DEPOLYMERASE) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Ralstonia Pickettii Poly (PHB DEPOLYMERASE) Protein (His) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P12625          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eP12625\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePoly(3-hydroxybutyrate) depolymerase; PHB depolymerase; EC 3.1.1.75\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRalstonia pickettii (Burkholderia pickettii)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eATAGPGAWSSQQTWAADSVNGGNLTGYFYWPASQPTTPNGKRALVLVLHGCVQTASGDVIDNANGAGFNWKSVADQYGAVILAPNATGNVYSNHCWDYANASPSRTAGHVGVLLDLVNRFVTNSQYAIDPNQVYVAGLSSGGGMTMVLGCIAPDIFAGIGINAGPPPGTTTAQIGYVPSGFTATTAANKCNAWAGSNAGKFSTQIAGAVWGTSDYTVAQAYGPMDAAAMRLVYGGNFTQGSQVSISGGGTNTPYTDSNGKVRTHEISVSGMAHAWPAGTGGDNTNYVDATHINYPVFVMDYWVKNNLRAGSGTGQAGSAPTGLAVTATTSTSVSLSWNAVANASSYGVYRNGSKVGSATATAYTDSGLIAGTTYSYTVTAVDPTAGESQPSAAVSATTKSAFTCTATTASNYAHVQAGRAHDSGGIAYANGSNQSMGLDNLFYTSTLAQTAAGYYIVGNCP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-488aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e50.9 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThis protein degrades water-insoluble and water-soluble PHB to monomeric D(-)-3-hydroxybutyrate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAB hydrolase superfamily, Lipase family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998900650209,"sku":"BLC-05169P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP319436BXV-SDS.jpg?v=1690510396"},{"product_id":"recombinant-treponema-pallidum-34-kda-membrane-antigen-tpd-protein-his-myc-blc-05222p","title":"Recombinant Treponema Pallidum 34 Kda Membrane Antigen (TPD) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Treponema Pallidum 34 Kda Membrane Antigen (TPD) Protein (His\u0026amp;Myc) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P19478          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTPD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003etpd; TP_0971; 34 kDa membrane antigen; Pathogen-specific membrane antigen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTreponema pallidum (strain Nichols)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCGGGGEHQHGEEMMAAVPAPDAEGAAGFDEFPIGEDRDVGPLHVGGVYFQPVEMHPAPGAQPSKEEADCHIEADIHANEAGKDLGYGVGDFVPYLRVVAFLQKHGSEKVQKVMFAPMNAGDGPHYGANVKFEEGLGTYKVRFEIAAPSHDEYSLHIDEQTGVSGRFWSEPLVAEWDDFEWKGPQW\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e20-204aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27.1 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThis antigen is a pathogen-specific membrane immunogen.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell membrane; Lipid-anchor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eUPF0423 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            tpa:TP_0971           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            243276.TP0971           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998905106657,"sku":"BLC-05222P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP322536TPR-1.jpg?v=1690566977"},{"product_id":"recombinant-treponema-pallidum-periplasmic-zinc-binding-protein-troa-troa-protein-his-myc-blc-05225p","title":"Recombinant Treponema Pallidum Periplasmic Zinc-Binding Protein Troa (TROA) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Treponema Pallidum Periplasmic Zinc-Binding Protein Troa (TROA) Protein (His\u0026amp;Myc) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P96116          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTROA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003etroA; troMP1; TP_0163; Periplasmic zinc-binding protein TroA; Tromp-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTreponema pallidum (strain Nichols)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFGSKDAAADGKPLVVTTIGMIADAVKNIAQGDVHLKGLMGPGVDPHLYTATAGDVEWLGNADLILYNGLHLETKMGEVFSKLRGSRLVVAVSETIPVSQRLSLEEAEFDPHVWFDVKLWSYSVKAVYESLCKLLPGKTREFTQRYQAYQQQLDKLDAYVRRKAQSLPAERRVLVTAHDAFGYFSRAYGFEVKGLQGVSTASEASAHDMQELAAFIAQRKLPAIFIESSIPHKNVEALRDAVQARGHVVQIGGELFSDAMGDAGTSEGTYVGMVTHNIDTIVAALAR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e23-308aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e38.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSignal Transduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePart of an ATP-driven transport system TroABCD for zinc. Substrate-binding protein involved in the transport of zinc across the cytoplasmic membrane.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePeriplasm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBacterial solute-binding protein 9 family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            tpa:TP_0163           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            243276.TP0163           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998906286305,"sku":"BLC-05225P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP309098TPR-1.jpg?v=1690566980"},{"product_id":"recombinant-treponema-phagedenis-treponemal-membrane-protein-b-tmpb-protein-his-myc-blc-05227p","title":"Recombinant Treponema Phagedenis Treponemal Membrane Protein B (TMPB) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Treponema Phagedenis Treponemal Membrane Protein B (TMPB) Protein (His\u0026amp;Myc) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P29720          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTMPB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003etmpB; Treponemal membrane protein B; Antigen TmpB\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTreponema phagedenis\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eISYDDNEYSRKSRAYTQLAEKAYDAGEYDTAIEYSQLAENFAQESAEYIKRMMARNEAEDAMNKARTRYAWAKQQKADKNYPTEYLIAGEAIKAGGIAFDNKNYDVAVTCAEKALESLKTVEPEDKVIAKAAADKAAAEKAAKEKAAREKSAKDKAAKEKAAKEKAAKDKAAKEKAAKEKAAKDKAAKEKAAKEKAAREMAAKEKAAKDKAAKEEAARKAAEEAAARKAAEEAAARKAAEEEAARIAAEEEAARKAAEEEAARKAAEEALYNEKGEKVLPSEYKVLTWKLDRECFWNIAKNPAVYNDPFMWRKLYEANKDKIPESNNPDWVEAETILVIPSIRGERREGLYDPDVKYQALPKR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e22-384aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e47.4 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTmp may serve as a porin or transport protein for large molecules.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCell outer membrane; Peripheral membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998906482913,"sku":"BLC-05227P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP333469THS-1.jpg?v=1690566990"},{"product_id":"recombinant-human-erythropoietin-epo-protein-his-active-blc-05911p","title":"Recombinant Human Erythropoietin (EPO) Protein (His), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin (EPO) Protein (His), Active is produced by our Mammalian cell expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 95% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eThe ED50 as determined in a cell proliferation assay using TF-1 human erythroleukemic cells is less than 5 ng\/ml\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P01588          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin; Epoetin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-193aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSignal Transduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2 μm filtered 1xPBS, pH 7.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3415           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133170           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2056           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000252723           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29395333            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the implication of alpha-7-nAChR-JAK-2\/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS            \u003ca rel=\"nofollow\"\u003e             PMID:                        29220591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28983059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27853265            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28603097            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28173069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29514032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28553927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27282568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26822707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            age 3 plasma levels of EPO were found related to childhood asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        27434124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28247960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28038963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO dependent regulation pathway of FGF23 gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        29073196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27161360            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        27266727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27981303            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27441662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27190272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +\/- 13.28 h) in comparison to epoetin alpha (8.5 +\/- 2.4 h) and darbepoetin alpha (25.3 +\/- 2.2h).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28168382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        27208431            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26747131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26479890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that EPO\/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27086036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27543111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPO is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem\/progenitor cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        27865586            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of contemporary aspects of EPO relating to chronic liver disease. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919118            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hepatic EPO synthesis is not enhanced in cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26924722            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26838000            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26097591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27081163            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inadequate erythropoietin response may partly explain anemia in anorexia nervosa.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26049959            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26012423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA\/MMP9-mediated proteolytic network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26469975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26995951            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25675872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447159            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage            \u003ca rel=\"nofollow\"\u003e             PMID:                        25628168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25793991            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"10ug","offer_id":43998970609889,"sku":"BLC-05911P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP003571HU.jpg?v=1690512366"},{"product_id":"recombinant-human-erythropoietin-protein-epo-active-blc-05912p","title":"Recombinant Human Erythropoietin Protein (EPO), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin Protein (EPO), Active is produced by our Mammalian cell expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 98% as determined by SDS-PAGE and HPLC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFully biologically active when compared to standard. The Specific Activity was measured by the stimulation of reticulocyte production in normocyth-aemic mice and was found to be no less than 1.5x10 5 IU\/mg.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P01588          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin; Epoetin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTag-Free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-193aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e21.0 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSterile filtered sodium citrate buffer (1 liter of ddH2O containing 5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3415           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133170           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2056           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000252723           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29395333            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the implication of alpha-7-nAChR-JAK-2\/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS            \u003ca rel=\"nofollow\"\u003e             PMID:                        29220591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28983059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27853265            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28603097            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28173069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29514032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28553927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27282568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26822707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            age 3 plasma levels of EPO were found related to childhood asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        27434124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28247960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28038963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO dependent regulation pathway of FGF23 gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        29073196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27161360            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        27266727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27981303            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27441662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27190272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +\/- 13.28 h) in comparison to epoetin alpha (8.5 +\/- 2.4 h) and darbepoetin alpha (25.3 +\/- 2.2h).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28168382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        27208431            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26747131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26479890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that EPO\/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27086036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27543111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPO is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem\/progenitor cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        27865586            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of contemporary aspects of EPO relating to chronic liver disease. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919118            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hepatic EPO synthesis is not enhanced in cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26924722            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26838000            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26097591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27081163            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inadequate erythropoietin response may partly explain anemia in anorexia nervosa.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26049959            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26012423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA\/MMP9-mediated proteolytic network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26469975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26995951            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25675872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447159            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage            \u003ca rel=\"nofollow\"\u003e             PMID:                        25628168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25793991            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"500IU","offer_id":43998970642657,"sku":"BLC-05912P","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-erythropoietin-protein-epo-active-blc-05913p","title":"Recombinant Human Erythropoietin Protein (EPO), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Erythropoietin Protein (EPO), Active is produced by our Mammalian cell expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 98% as determined by SDS-PAGE and HPLC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFully biologically active when compared to standard. The Specific Activity was measured by the stimulation of reticulocyte production in normocyth-aemic mice and was found to be no less than 1.5x10 5 IU\/mg.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P01588          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin; Epoetin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eTag-Free\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-193aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e21.0 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2μm filtered sodium citrate buffer (1 liter of ddH2O containing 5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3415           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133170           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2056           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000252723           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29395333            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the implication of alpha-7-nAChR-JAK-2\/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS            \u003ca rel=\"nofollow\"\u003e             PMID:                        29220591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28983059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27853265            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28603097            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28173069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29514032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28553927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27282568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26822707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            age 3 plasma levels of EPO were found related to childhood asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        27434124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28247960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28038963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO dependent regulation pathway of FGF23 gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        29073196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27161360            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        27266727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27981303            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27441662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27190272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +\/- 13.28 h) in comparison to epoetin alpha (8.5 +\/- 2.4 h) and darbepoetin alpha (25.3 +\/- 2.2h).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28168382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        27208431            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26747131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26479890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that EPO\/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27086036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27543111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPO is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem\/progenitor cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        27865586            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of contemporary aspects of EPO relating to chronic liver disease. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919118            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hepatic EPO synthesis is not enhanced in cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26924722            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26838000            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26097591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27081163            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inadequate erythropoietin response may partly explain anemia in anorexia nervosa.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26049959            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26012423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA\/MMP9-mediated proteolytic network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26469975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26995951            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25675872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447159            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage            \u003ca rel=\"nofollow\"\u003e             PMID:                        25628168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25793991            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"500IU","offer_id":43998970872033,"sku":"BLC-05913P","price":0.0,"currency_code":"USD","in_stock":true}]},{"product_id":"recombinant-human-epo-alpha-fc-chimera-protein-epo-protein-hfc-active-blc-05914p","title":"Recombinant Human Epo-Alpha\/Fc Chimera Protein (EPO) Protein (hFc), Active","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Epo-Alpha\/Fc Chimera Protein (EPO) Protein (hFc), Active is produced by our Mammalian cell expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 98% as determined by SDS-PAGE and HPLC.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eEndotoxin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLess than 1.0 EU\/μg as determined by LAL method.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFully biologically active when compared to standard. The Specific Activity was measured by the stimulation of reticulocyte production in normocyth-aemic mice and is no less than 5.0 × 10^5 IU\/mg.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P01588          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin; Epoetin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-hFc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eComplete Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR+IEGRMDEPKSSDKTHTCPPCPAPEFEGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPTPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e28-193aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e45.3 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLyophilized from a 0.2μm filtered sodium citrate buffer (1 liter of ddH2O containing 5.9 g of sodium citrate, 5.8 g of sodium chloride and 0.06 g of citric acid)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            3415           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            133170           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:2056           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9606.ENSP00000252723           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        29395333            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            the implication of alpha-7-nAChR-JAK-2\/STAT-3-Nrf-2 signaling cascade in the radiomitigative potential of EPO against ARS            \u003ca rel=\"nofollow\"\u003e             PMID:                        29220591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pro-inflammatory proteins S100A9 and tumor necrosis factor-alpha suppress erythropoietin elaboration in myelodysplastic syndromes            \u003ca rel=\"nofollow\"\u003e             PMID:                        28983059            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels in the coronary artery disease (CAD) group were higher than those in the non-CAD group. The correlation between red cell distribution width and EPO levels was statistically significant among CAD patients.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28885393            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CD133(+) cells contributed to the local production of erythropoietin, as observed by detection of circulating human erythropoietin. CD133(+) cells appear therefore an effective source for cell repair, able to restore renal functions, including erythropoietin release, and to limit long term maldifferentiation and fibrosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27853265            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Circulating anti-EPO are detected in a significant proportion of treatment-naive HCV-infected patients and are independently associated with anemia, suggesting a further implication of autoimmunity in the pathophysiology of HCV-related anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28603097            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the T allele of SNP rs60684937 located at 67,419,130 bp on chromosome 17 was associated with increased plasma EPO and a relatively increased expression of a non-coding transcript of PRKAR1A in sickle cell disease patients            \u003ca rel=\"nofollow\"\u003e             PMID:                        28173069            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            study describes a gain-of-function variant in EPO in an extended kindred with familial erythrocytosis, including 10 affected family members in four generations; this mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2            \u003ca rel=\"nofollow\"\u003e             PMID:                        29514032            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Here, using zebrafish, murine, and human models, the authors show that erythropoietin (EPO) signaling, together with the GATA1 transcriptional target, AKAP10, regulates heme biosynthesis during erythropoiesis at the outer mitochondrial membrane.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28553927            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Reduction in central venous blood pressure prompts an increase in plasma EPO concentration independent of hemoconcentration and hence suggests CVP per se as an acute regulator of EPO synthesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27169519            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO (7q22) and SEC-61(7p11) emerged as new candidate genes susceptible to genetic losses with 57.7% deletions identified in regions on chromosome 7.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27282568            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The current controversy may derive from a context-dependent mode of action of Epo, namely opposite skeletal actions during bone regeneration and steady-state bone remodeling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26822707            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            High EPO expression is associated with monoclonal gammopathy of undetermined significance and multiple myeloma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919105            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            age 3 plasma levels of EPO were found related to childhood asthma            \u003ca rel=\"nofollow\"\u003e             PMID:                        27434124            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO induces an EMT-like process in mammary non-tumorigenic epithelial cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        28247960            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these results suggested that quercetin's cytoprotective effects in HepG2 cells are mediated via EPO production.            \u003ca rel=\"nofollow\"\u003e             PMID:                        29080630            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Serum Epo and VEGF may be markers of severity of hypoxia-ischaemia and brain injury as they are closely related to hypoxic exposure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27902983            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            CIS interacted with phosphorylated EpoR at Y401, which was critical for the activation of STAT5 and ERK.            \u003ca rel=\"nofollow\"\u003e             PMID:                        28038963            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO dependent regulation pathway of FGF23 gene expression            \u003ca rel=\"nofollow\"\u003e             PMID:                        29073196            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Fetal plasma EPO concentrations are selectively increased in monochorionic twin pregnancies with intrauterine growth restriction.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27161360            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this study shows that EPO is involved in the pathogenesis of sepsis-induced acute kidney injury            \u003ca rel=\"nofollow\"\u003e             PMID:                        27266727            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality in patients with acute-on-chronic liver failure.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27981303            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO levels were also found correlated positively with heme, TNF-alpha, IL-10, IP-10 and MCP-1 during cerebral malaria.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27441662            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Three single nucleotide polymorphisms are associated with increased risk of diabetic retinopathy in a Chinese Han population.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27190272            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Pharmacokinetic animal studies revealed strongly 15.6-fold plasma half-life extension for the PASylated EPO (83.16 +\/- 13.28 h) in comparison to epoetin alpha (8.5 +\/- 2.4 h) and darbepoetin alpha (25.3 +\/- 2.2h).            \u003ca rel=\"nofollow\"\u003e             PMID:                        28168382            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Secreted MIR122 reached the kidney and reduced expression of erythropoietin, contributing to inflammation-induced anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27477940            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            this paper shows that Epo could directly down-regulate pro-inflammatory T cell responses without affecting T cell activation status            \u003ca rel=\"nofollow\"\u003e             PMID:                        27208431            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            findings suggest that erythropoietin levels in anemia of unknown etiology, although elevated, remain inappropriately low, particularly when compared with other forms of anemia. This suggests a relative erythropoietin deficiency or a blunted erythroid cell response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26747131            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Plasma IGFBP-1 was significantly associated with plasma EPO concentration in acute kidney injury, suggesting an unknown mechanism related to systemic stress conditions for EPO regulation in AKI.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26479890            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our results suggest that EPO\/EPOR pathway promotes gastric cancer formation, proliferation, migration, and decreases apoptosis            \u003ca rel=\"nofollow\"\u003e             PMID:                        27086036            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These results suggest that both EpoR-positive and EpoR-negative cancer cells could be regulated by exogenous Epo. However, an increased response to erythropoietin was observed in the EpoR-positive cells. Thus, erythropoietin increases the risk of tumor progression in colon cancer and should not be used to treat anemia in this type of cancer.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27543111            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Overexpression of EPO is associated with clear cell renal cell carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27468719            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO may play an important role in stem cell mobilization through up regulating HGF in mesenchymal stem cells and inducing migration of hematopoietic stem\/progenitor cells            \u003ca rel=\"nofollow\"\u003e             PMID:                        27865586            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            A review of contemporary aspects of EPO relating to chronic liver disease. [review]            \u003ca rel=\"nofollow\"\u003e             PMID:                        26919118            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hepatic EPO synthesis is not enhanced in cirrhosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26924722            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Conclusion: Anemia in cancers was not because of inadequate Epo or Fe levels, but because of improper Epo response.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26838000            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In multivariate survival analysis, age, Epo and EpoR were independent prognostic factors related to overall survival in hepatocellular carcinoma.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26097591            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Suggest that hypoxia prevents EPO suppression, and exaggerates the plasma volume reduction induced by bed rest.            \u003ca rel=\"nofollow\"\u003e             PMID:                        27081163            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Inadequate erythropoietin response may partly explain anemia in anorexia nervosa.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26049959            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            these findings suggest that TGF-beta suppression and EPO stimulation promote erythropoiesis of CD34(+)CD31(+) progenitor cells derived from hPSCs.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26012423            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our findings have important potential clinical implications, indicating that EPO supplementation in rhabdomyosarcoma patients may have the unwanted side effect of tumor progression.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26412593            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            suggest that rhEPO regulates apoptosis-related genes and affects apoptosis in the hippocampus of aging rats by upregulating SIRT.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26261574            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Higher levels of endogenous erythropoietin are associated with incident heart failure in older adults.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26721912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Erythropoietin protects mouse renal tubular basement membrane by promoting bone marrow cells to generate and secrete miR-144, which, in turn, inhibits activation of the tPA\/MMP9-mediated proteolytic network.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26469975            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The review describes the induction of erythropoietin gene expression in liver, reproouctive and hemopoietic systems during hypoxia or a state of proliferation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26995951            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Our data suggest that rs507392 and rs551238 in the erythropoietin gene probably act to lessen the risk for diabetic retinopathy (DR) in a Chinese cohort with type 2 diabetes mellitus (T2DM).            \u003ca rel=\"nofollow\"\u003e             PMID:                        25675872            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest maternal circulating 25-hydroxyvitamin D during mid-pregnancy and at delivery is inversely related to serum EPO; an indirect relation observed between circulating vitamin D and circulating hemoglobin is at least partly mediated by EPO.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26447159            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            This review gleans these different strategies and highlights the leading molecular recognition elements that have potential roles in rHuEPO doping detection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25058943            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The addition of salt (even low concentrations of the strong chaotrope salt guanidinium hydrochloride) also exponentially decreased the initial rate of soluble erythropoietin non-native aggregation at 37 degrees C storage            \u003ca rel=\"nofollow\"\u003e             PMID:                        25628168            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, was determined.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25793991            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"2ug","offer_id":43998971101409,"sku":"BLC-05914P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-AP002091HU.jpg?v=1690512371"},{"product_id":"recombinant-rat-erythropoietin-receptor-epor-protein-his-gb1-his-blc-06138p","title":"Recombinant Rat Erythropoietin Receptor (EPOR) Protein (His-GB1\u0026His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat Erythropoietin Receptor (EPOR) Protein (His-GB1\u0026amp;His) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q07303          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpor; Erythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRattus norvegicus (Rat)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-GB1\u0026amp;C-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eASSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAANSGMGFNYSFSYQLEGESRKSCRLHQAPTVRGSMRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-249aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e36.6 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10116.ENSRNOP00000017369           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Rn\u0026amp;CID=22394\"\u003e            Rn.22394           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIsoform EPOR-F and isoform EPOR-S are expressed in bone marrow, spleen and eythroleukemia cell lines.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43998999740641,"sku":"BLC-06138P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007744RAg9-SDS.jpg?v=1690512958"},{"product_id":"recombinant-rat-erythropoietin-receptor-epor-protein-his-blc-06152p","title":"Recombinant Rat Erythropoietin Receptor (EPOR) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat Erythropoietin Receptor (EPOR) Protein (His) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q07303          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpor; Erythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRattus norvegicus (Rat)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eASSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAANSGMGFNYSFSYQLEGESRKSCRLHQAPTVRGSMRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-249aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25.7 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10116.ENSRNOP00000017369           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Rn\u0026amp;CID=22394\"\u003e            Rn.22394           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIsoform EPOR-F and isoform EPOR-S are expressed in bone marrow, spleen and eythroleukemia cell lines.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999002296545,"sku":"BLC-06152P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007744RA-SDS.jpg?v=1690513002"},{"product_id":"recombinant-zebrafish-erythropoietin-epo-protein-his-blc-06162p","title":"Recombinant Zebrafish Erythropoietin (EPO) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Zebrafish Erythropoietin (EPO) Protein (His) is produced by our Yeast expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q2XNF5          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eepo; Erythropoietin; Erythropoietin-L2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eDanio rerio (Zebrafish) (Brachydanio rerio)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eYeast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSPLRPICDLRVLDHFIKEAWDAEAAMRTCKDDCSIATNVTVPLTRVDFEVWEAMNIEEQAQEVQSGLHMLNEAIGSLQISNQTEVLQSHIDASIRNIASIRQVLRSLSIPEYVPPTSSGEDKETQKISSISELFQVHVNFLRGKARLLLANAPVCRQGVS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e24-183aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e19.8\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eErythropoietin is the principal hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            dre:100004455           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            7955.ENSDARP00000100433           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        17706649            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            characterization of zebrafish epo and epor demonstrates the conservation of an ancient program that ensures proper red blood cell numbers during normal homeostasis and under hypoxic conditions            \u003ca rel=\"nofollow\"\u003e             PMID:                        17579187            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999003377889,"sku":"BLC-06162P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-YP007743DILa0-SDS.jpg?v=1690513043"},{"product_id":"recombinant-rat-erythropoietin-receptor-epor-protein-his-blc-06349p","title":"Recombinant Rat Erythropoietin Receptor (EPOR) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Rat Erythropoietin Receptor (EPOR) Protein (His) is produced by our Mammalian cell expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q07303          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRattus norvegicus (Rat)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMammalian cell\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eASSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAANSGMGFNYSFSYQLEGESRKSCRLHQAPTVRGSMRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-249aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e27.5 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMembrane; Single-pass type I membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10116.ENSRNOP00000017369           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Rn\u0026amp;CID=22394\"\u003e            Rn.22394           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eIsoform EPOR-F and isoform EPOR-S are expressed in bone marrow, spleen and eythroleukemia cell lines.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999026446561,"sku":"BLC-06349P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-MP007744RA-SDS.jpg?v=1690513785"},{"product_id":"recombinant-human-epoxide-hydrolase-3-ephx3-protein-his-myc-blc-07295p","title":"Recombinant Human Epoxide Hydrolase 3 (EPHX3) Protein (His\u0026Myc)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Human Epoxide Hydrolase 3 (EPHX3) Protein (His\u0026amp;Myc) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           Q9H6B9          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPHX3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHomo sapiens (Human)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-10His\u0026amp;C-Myc\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eALTHVLCRPRRGCCGRRRSASPACLSDPSLGEHGFLNLKSSGLRLHYVSAGRGNGPLMLFLHGFPENWFSWRYQLREFQSRFHVVAVDLRGYGPSDAPRDVDCYTIDLLLVDIKDVILGLGYSKCILVAHDWGALLAWHFSIYYPSLVERMVVVSGAPMSVYQDYSLHHISQFFRSHYMFLFQLPWLPEKLLSMSDFQILKTTLTHRKTGIPCLTPSELEAFLYNFSQPGGLTGPLNYYRNLFRNFPLEPQELTTPTLLLWGEKDTYLELGLVEAIGSRFVPGRLEAHILPGIGHWIPQSNPQEMHQYMWAFLQDLLD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e43-360aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e43.9 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCatalyzes the hydrolysis of epoxide-containing fatty acids. Active in vitro against epoxyeicosatrienoic acids (EETs) including 8,9-EET, 9,10-EET, 11,12-EET and 14,15-EET and leukotoxin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMicrosome membrane; Single-pass membrane protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAB hydrolase superfamily, Epoxide hydrolase family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           HGNC:           \u003ca rel=\"nofollow\"\u003e            23760           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           OMIM:           \u003ca rel=\"nofollow\"\u003e            617400           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            hsa:79852           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        24718283            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            The identification of two human epoxide hydrolases: EH3 and EH4.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22798687            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            methylation of the ABHD9 is significantly associated with prostate cancer prognosis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17437806            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999166660833,"sku":"BLC-07295P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007736HU-SDS.jpg?v=1690517295"},{"product_id":"recombinant-mouse-erythropoietin-receptor-epor-protein-his-blc-07593p","title":"Recombinant Mouse Erythropoietin Receptor (EPOR) Protein (His)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Mouse Erythropoietin Receptor (EPOR) Protein (His) is produced by our E.coli expression system. This is a protein fragment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 85% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P14753          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEpor; Erythropoietin receptor; EPO-R\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eMus musculus (Mouse)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eC-10His\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPSPSLPDPKFESKAALLASRGSEELLCFTQRLEDLVCFWEEAASSGMDFNYSFSYQLEGESRKSCSLHQAPTVRGSVRFWCSLPTADTSSFVPLELQVTEASGSPRYHRIIHINEVVLLDAPAGLLARRAEEGSHVVLRWLPPPGAPMTTHIRYEVDVSAGNRAGGTQRVEVLEGRTECVLSNLRGGTRYTFAVRARMAEPSFSGFWSAWSEPASLLTASDLDP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e25-249aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003ePartial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26.2 kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eCardiovascular\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eReceptor for erythropoietin. Mediates erythropoietin-induced erythroblast proliferation and differentiation. Upon EPO stimulation, EPOR dimerizes triggering the JAK2\/STAT5 signaling cascade. In some cell types, can also activate STAT1 and STAT3. May also activate the LYN tyrosine kinase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e[Isoform EPOR-F]: Cell membrane; Single-pass type I membrane protein.; [Isoform EPOR-S]: Secreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eType I cytokine receptor family, Type 1 subfamily\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            mmu:13857           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            10090.ENSMUSP00000006397           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca rel=\"nofollow\"\u003e             PMID:                        27998978            \u003c\/a\u003e  \u003c\/p\u003e\n\u003cli\u003e            A solution NMR study of the mouse erythropoietin receptor (mEpoR) comprising the transmembrane domain and the juxtamembrane regions reconstituted in dodecylphosphocholine (DPC) micelles.            \u003ca rel=\"nofollow\"\u003e             PMID:                        26316120            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            loss of function results in defective macrophage clearance of apoptotic cells in vivo            \u003ca rel=\"nofollow\"\u003e             PMID:                        26872696            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data indicate that EpoR signaling is associated with cardiac remodeling following chronic iron deficiency.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25715089            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            We propose that the CID-dependent dimerization system combined with the EpoR intracellular domain and the Gata1 gene regulatory region generates a novel peroral strategy for the treatment of anemia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        25790231            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles            \u003ca rel=\"nofollow\"\u003e             PMID:                        25418301            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR and its activity are downstream effectors of Klotho enabling it to function as a cytoprotective protein against oxidative injury.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23636173            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Expression of EPOR in rod photoreceptors, Muller cells, and amacrine, horizontal, and ganglion cells of the peripheral retina is not required for the maturation, function, and survival of these cells in aging tissue.            \u003ca rel=\"nofollow\"\u003e             PMID:                        24644405            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data from knockout mice suggest that adipose tissue-specific disruption of EPO receptor does not alter adipose tissue expansion, adipocyte morphology, insulin resistance, inflammation, or angiogenesis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23885016            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the EPO-EPOR system may play a role in glucose metabolism within adipocytes.            \u003ca rel=\"nofollow\"\u003e             PMID:                        23313788            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPOR regulates transcriptome for primary progenitors, including Tnfr-sf13c as a novel mediator of EPO-dependent erythroblast formation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22808010            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expression of EPOR decreased with the development of renal cortex            \u003ca rel=\"nofollow\"\u003e             PMID:                        22844537            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            enhanced activation of signaling pathways downstream of the EPO-receptor, indicate that SH2B1 is a negative regulator of EPO signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        22669948            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EPO\/EPOR signaling from astrocyte to oligodendrocyte progenitor cells (OPC) prevents OPC damage under hypoxic\/reoxygenation conditions.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21833990            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Postmortem neural precursor cells differentiate mostly in self-renewable neurons, show activation, and express both erythropoietin (EPO) and its receptor (EPO-R).            \u003ca rel=\"nofollow\"\u003e             PMID:                        21324364            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            expressed in both non-wounded and wounded skin tissue as well as in fibroblasts and keratinocytes            \u003ca rel=\"nofollow\"\u003e             PMID:                        21894148            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Gata4 or Sp1 may limit the accessibility of the EpoR for binding of erythropoiesis-stimulating agents.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21029371            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Mice with transgenic expression of a constitutively active erythropoietin receptor isoform in pyramidal neurons of cortex and hippocampus exhibit enhancement of spatial learning, cognitive flexibility, social memory, and attentional capacities.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21527022            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The Epo\/EpoR complex plays a critical role in the adhesion and migration of rat fibroblasts, and its functional inactivation is associated with PLC-gammal-dependent reduction of cell-matrix adhesion and this also affects cell migration.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21360263            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            genetic ablation promotes Salmonella elimination            \u003ca rel=\"nofollow\"\u003e             PMID:                        21256055            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            These data provide evidence of a role for nitric oxide in erythropoietin activity in brain and suggest links between NO production, EpoR expression, and Epo signaling in neuroprotection.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20806411            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The phosphorylation of EpoR at Y479 is required for oncogenic signaling of JAK2 V617F mutant and that targeted disruption of this pathway has therapeutic utility.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21255641            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            ubiquitination of the EpoR critically controls both receptor down-regulation and downstream signaling.            \u003ca rel=\"nofollow\"\u003e             PMID:                        21183685            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Darbepoetin stimulates multiple cardioprotective mechanisms in infarcted myocardium to improve cardiac function independent of erythropoietin receptor-common beta-chain heteroreceptor.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20649603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            regional specific up-regulation of EPOR at an early stage after MPTP stimulus may represent a pro-survival mechanism against neurotoxin injury in Parkinsonian model            \u003ca rel=\"nofollow\"\u003e             PMID:                        19537929            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            rapid ligand depletion \u0026amp; replenishment of cell surface receptor are characteristic of EpoR; Epo-EpoR complexes \u0026amp; EpoR activation integrated over time correspond linearly to ligand input; relation depends on EpoR turnover            \u003ca rel=\"nofollow\"\u003e             PMID:                        20488988            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the presence of EpoR is required to activate oncogenic signaling via the JAK2 mutant and STAT5, its interacting ability is a target for the treatment of these hematopoietic diseases.            \u003ca rel=\"nofollow\"\u003e             PMID:                        20028972            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor            \u003ca rel=\"nofollow\"\u003e             PMID:                        11779507            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Epo receptor cytoplasmic domain conformation is essential for the initiation of signal transduction            \u003ca rel=\"nofollow\"\u003e             PMID:                        11997394            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            developmental defect of PrlR(-\/-) mammary epithelium is rescued by an exogenously expressed chimeric receptor (prl-EpoR) containing the PrlR extracellular domain joined to the EpoR transmembrane and intracellular domains            \u003ca rel=\"nofollow\"\u003e             PMID:                        12381781            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            demonstration of an essential role for Src pathway in regulating growth, proliferation, and cooperation with Epo-Receptor downstream from Kit            \u003ca rel=\"nofollow\"\u003e             PMID:                        12486028            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            C-hexosylation of the WSAWS motif did not play a role in the correct intracellular transport of sEPOR            \u003ca rel=\"nofollow\"\u003e             PMID:                        12859190            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the function of JAK2-coupled but phosphotyrosine-null Epo form appears to be attenuated in several contexts and to be assisted in vivo by compensatory mechanisms.            \u003ca rel=\"nofollow\"\u003e             PMID:                        12869513            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the Epo receptor Tyr-343 Stat5 pathway has a role in proliferative co-signaling with kit            \u003ca rel=\"nofollow\"\u003e             PMID:                        12909618            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            EpoR can be activated to different extents by homodimeric gp55 proteins, depending on the conformation of the gp55 protein dimer in the TM region            \u003ca rel=\"nofollow\"\u003e             PMID:                        12930840            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            erythropoietin receptor transmembrane segments self-interaction depends on a membrane-spanning leucine zipper            \u003ca rel=\"nofollow\"\u003e             PMID:                        14602718            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Data suggest that the activity of the erythropoietin receptor is determined by the helical periodicity or orientation of the transmembrane and cytosolic domains.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14636581            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            results elucidate a previously unrecognized hematopoietic cell survival pathway elicited by the EPOR, that requires Stat5 and is serum independent.            \u003ca rel=\"nofollow\"\u003e             PMID:                        14662339            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            a functional EPO-R may be necessary and sufficient for TPO to exert its mitogenic effects on erythroid cells.            \u003ca rel=\"nofollow\"\u003e             PMID:                        15102474            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Knockout mice exhibit normal erythrocyte maturation, so receptor is not resquired for erythropoiesis            \u003ca rel=\"nofollow\"\u003e             PMID:                        15456912            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            the TM-JM junction of EpoR forms an N-terminal helix cap required for function            \u003ca rel=\"nofollow\"\u003e             PMID:                        15657048            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Friend virus activates both sf-STK and the EPOR to cause deregulated erythroid proliferation and differentiation.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16174761            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In knockout mice, epoietein induced reticulocyte and erythroblast maturation were attenuated.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16332976            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            analysis of gene expression induced by erythropoietin receptor structural variants            \u003ca rel=\"nofollow\"\u003e             PMID:                        16380376            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            model of the active and inactive conformations of the Epo receptor            \u003ca rel=\"nofollow\"\u003e             PMID:                        16414957            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The classical EPOR is essential for EPO action during embryonic neurogenes \u0026amp; is important for adult neurogenesis and for migration of regenerating neurons during post-injury recovery.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16436614            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Stress erythropoiesis during anemia is rescued to wild type levels upon the selective restoration of an EpoR-phosphotyrosine-Stat5-binding site signaling axis.            \u003ca rel=\"nofollow\"\u003e             PMID:                        16511603            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            The vascular EpoR system plays an important role in angiogenesis in response to hindlimb ischemia through upregulation of the vascular endothelial growth factor\/VEGF receptor system.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17293480            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            In mice expressing an EpoR allele, compromised erythropoietin-induced podocalyxin expression correlated with enucleated red cells in bone marrow.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17403918            \u003c\/a\u003e \u003c\/li\u003e \u003cli\u003e            Hypoxic downregulation of sEpoR is required for adequate ventilatory acclimatization to hypoxia.            \u003ca rel=\"nofollow\"\u003e             PMID:                        17584830            \u003c\/a\u003e \u003c\/li\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999208341729,"sku":"BLC-07593P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007744MO1-SDS.jpg?v=1690518434"},{"product_id":"recombinant-bovine-erythropoietin-epo-protein-his-sumo-blc-09238p","title":"Recombinant Bovine Erythropoietin (EPO) Protein (His-SUMO)","description":"\u003cmeta charset=\"utf-8\"\u003e\u003ch3\u003eProduct Overview\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDescription\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRecombinant Bovine Erythropoietin (EPO) Protein (His-SUMO) is produced by our E.coli expression system. This is a full length protein.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003ePurity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eGreater than 90% as determined by SDS-PAGE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eUniprotkb\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003ca rel=\"nofollow\" target=\"_blank\"\u003e           P48617          \u003c\/a\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Symbol\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPOErythropoietin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSpecies\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBos taurus (Bovine)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eE.coli\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTag\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eN-6His-SUMO\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Protein Sequence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eAPARLICDSRVLERYILEAREAENATMGCAEGCSFNENITVPDTKVNFYAWKRMEVQQQALEVWQGLALLSEAILRGQALLANASQPCEALRLHVDKAVSGLRSLTSLLRALGAQKEAISLPDATPSAAPLRAFTVDALSKLFRIYSNFLRGKLTLYTGEACRRGDR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eExpression Range\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e26-192aa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Length\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eFull Length of Mature Protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eMol. Weight\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e34.4kDa\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eResearch Area\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eOthers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eForm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid or Lyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eBuffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eLiquid form: default storage buffer is Tris\/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris\/PBS-based buffer, 6% Trehalose, pH 8.0.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eReconstitution\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eBriefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg\/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C\/-80°C. The default final concentration of glycerol is 50%.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eStorage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e1. Store at -20°C\/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C\/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C\/-80°C.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eNotes\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eRepeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e \u003ch3\u003eTarget Details\u003c\/h3\u003e\u003ctable width=\"100%\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTarget Function\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eHormone involved in the regulation of erythrocyte proliferation and differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Binds to EPOR leading to EPOR dimerization and JAK2 activation thereby activating specific downstream effectors, including STAT1 and STAT3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eSubcellular Location\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eSecreted.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eProtein Families\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eEPO\/TPO family\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eDatabase References\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003e\u003cdiv\u003e \u003cp\u003e           KEGG:           \u003ca rel=\"nofollow\"\u003e            bta:280784           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           STRING:           \u003ca rel=\"nofollow\"\u003e            9913.ENSBTAP00000004450           \u003c\/a\u003e \u003c\/p\u003e \u003cp\u003e           UniGene:           \u003ca href=\"https:\/\/www.ncbi.nlm.nih.gov\/UniGene\/clust.cgi?ORG=Bt\u0026amp;CID=525\"\u003e            Bt.525           \u003c\/a\u003e \u003c\/p\u003e \u003c\/div\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 30%;\"\u003e\u003cstrong\u003eTissue Specificity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 70%;\"\u003eProduced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e","brand":"Beta LifeScience","offers":[{"title":"20ug","offer_id":43999415238881,"sku":"BLC-09238P","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/products\/CSB-EP007743BO-SDS.jpg?v=1690523658"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0624\/2169\/6737\/collections\/HUMAN_ERYTHROPOIETIN_EPO_Structure.jpg?v=1778544317","url":"https:\/\/www.betalifesci.com\/collections\/epo-protein-overview-applications-selection-guide.oembed?page=2","provider":"Beta LifeScience","version":"1.0","type":"link"}